As
filed with the U.S. Securities and Exchange Commission on July 26, 2023.
Registration
Statement No. 333-272128
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
Amendment
No. 6 to
FORM
S-1
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
ARIDIS
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
2834 |
|
47-2641188 |
(State
or other jurisdiction of
incorporation or organization) |
|
(Primary
Standard Industrial
Classification Code Number) |
|
(I.R.S.
Employer
Identification Number) |
983
University Avenue, Bldg. B
Los
Gatos, California 95032
(408)
385-1742
(Address
and telephone number of registrant’s principal executive offices)
Dr.
Vu L. Truong
Chief
Executive Officer
Aridis
Pharmaceuticals, Inc.
983
University Avenue, Bldg. B
Los
Gatos, California 95032
(408)
385-1742
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to: |
Jeffrey
J. Fessler, Esq.
Sheppard,
Mullin, Richter & Hampton LLP
30
Rockefeller Plaza
New
York, New York 10112-0015
(212)
653-8700 |
|
Robert
F. Charron, Esq. Ellenoff
Grossman & Schole LLP
1345
Avenue of the Americas, 11th Fl. New
York, New York 10105
(212)
370-1300
|
Approximate
date of commencement of proposed sale to the public:
As
soon as practicable after the effective date of this registration statement becomes effective.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the
following box: ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ |
Accelerated filer ☐ |
Non-accelerated filer ☒ |
Smaller
reporting company ☒
Emerging
growth company ☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐
The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject
to completion, dated July 26, 2023
Preliminary
Prospectus
Up
to 9,090,909 Shares of Common Stock
9,090,909
Pre-Funded Warrants to Purchase up to 9,090,909
Shares of Common Stock
9,090,909
Warrants to Purchase up to 9,090,909
Shares of Common Stock
Up
to 18,181,818 Shares of Common Stock underlying the Pre-Funded Warrants and Warrants

Aridis
Pharmaceuticals, Inc.
We
are offering up to 9,090,909 shares of our common stock together with 9,090,909 warrants to purchase up to 9,090,909
shares of common stock. Each share of our common stock, or a pre-funded warrant in lieu thereof as described below, is being sold
together with one warrant to purchase one share of our common stock (a “common warrant”). The shares of common stock and
common warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering.
The assumed public offering price for one share of common stock and accompanying common warrant is $0.22, which was the last reported
sale price of our common stock on the OTC Markets Pink Sheets trading system on July 24, 2023. Each common warrant will have an
exercise price per share of $____ and will be exercisable beginning on the date of issuance. The common warrants will expire on the five-year
anniversary of the date of issuance.
We
are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser,
together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser,
9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such
purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial
ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. The public offering price of
one pre-funded warrant and accompanying common warrant will be equal to the price at which one share of common stock and accompanying
common warrant is sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded warrant will be $0.0001
per share. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants
are exercised in full. The pre-funded warrants and common warrants are immediately separable and will be issued separately in this offering,
but must be purchased together in this offering. For each pre-funded warrant we sell, the number of shares of common stock we are offering
will be decreased on a one-for-one basis.
This
offering will terminate on August 4, 2023, unless we decide to terminate the offering (which we may do at any time in our discretion)
prior to that date. We will have one closing for all the securities purchased in this offering. The public offering price per share (or
pre-funded warrant) and accompanying common warrant will be fixed for the duration of this offering.
Until
July 18, 2023, our common stock was listed on The Nasdaq Capital Market under the symbol “ARDS.” On July 17, 2023, we received
written notice from the Nasdaq Stock Market, LLC that it would delist our shares of common stock from the Nasdaq Capital Market upon
the opening of trading on July 19, 2023. As of July 19, 2023, our common stock was quoted on the OTC Markets Pink Sheets trading system.
On July 24, 2023, the last report sale price of our common stock on the OTC Markets Pink Sheets was $0.22 per share.
The public offering price per share of common stock
and accompanying common warrant and per pre-funded warrant and accompanying common warrant will be determined between us and the investors
based on market conditions at the time of pricing, and may be at a discount to the then current market price of our common stock. The
recent market price used throughout this prospectus may not be indicative of the actual offering price. The actual public offering price
may be based upon a number of factors, including our history and our prospects, the industry in which we operate, our past and present
operating results, the previous experience of our executive officers and the general condition of the securities markets at the time
of this offering. There is no established public trading market for the pre-funded warrants and the common warrants and we do not expect
a market to develop. Without an active trading market, the liquidity of the pre-funded warrants and the common warrants will be limited.
In addition, we do not intend to list the pre-funded warrants or the common warrants on the OTC Markets Pink Sheets, any national securities
exchange or any other trading system.
We have engaged H.C. Wainwright & Co., LLC,
or the placement agent, to act as our exclusive placement agent in connection with this offering. The placement agent has agreed
to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing
or selling any of the securities we are offering and the placement agent is not required to arrange the purchase or sale of any specific
number of securities or dollar amount. We have agreed to pay to the placement agent the placement agent fees set forth in the table below,
which assumes that we sell all of the securities offered by this prospectus. There is no arrangement for funds to be received in escrow,
trust or similar arrangement. There is no minimum offering requirement as a condition of closing of this offering. Because there is no
minimum offering amount required as a condition to closing this offering, we may sell fewer than all of the securities offered hereby,
which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the
event that we do not sell all of the securities offered hereby. We will bear all costs associated with the offering. See “Plan
of Distribution” on page 122 of this prospectus for more information regarding these arrangements.
We
are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act,
and, as such, have elected to comply with certain reduced public company reporting requirements.
Investing
in our securities involves a high degree of risk. See “Risk Factors” beginning on page 6 of
this prospectus for a discussion of information that should be considered in connection with an investment in our securities.
Neither
the Securities and Exchange Commission, nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
| |
Per Share and
Common Warrant | | |
Per Pre- Funded
Warrant and
Common
Warrant | | |
Total | |
Public offering price | |
$ | | | |
$ | | | |
$ | | |
Placement agent fees(1) | |
$ | | | |
$ | | | |
$ | | |
Proceeds to us, before expenses | |
$ | | | |
$ | | | |
$ | | |
(1) | We
have also agreed to reimburse the placement agent for certain of its offering-related expenses,
including a reimbursement for legal fees and expenses in the amount of up to $100,000, $20,000
for its non-accountable expense in the offering, and for its clearing expenses in the amount
of $15,950. For a description of the compensation to be received by the placement agent,
see “Plan of Distribution” for more information. |
The
placement agent expects to deliver the securities to the purchasers on or about July __, 2023, subject to satisfaction of customary
closing conditions.
H.C. Wainwright & Co.
The
date of this prospectus is , 2023
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
We
incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without
charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus
as well as additional information described under “Information Incorporated by Reference,” before deciding to invest in our
securities.
Neither
we nor the placement agent has authorized anyone to provide you with additional information or information different from that
contained or incorporated by reference in this prospectus filed with the Securities and Exchange Commission (the “SEC”).
We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
The placement agent is offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted.
The information contained in this prospectus, or any document incorporated by reference in this prospectus, is accurate only as of the
date of those respective documents, regardless of the time of delivery of this prospectus or any sale of our securities. Our business,
financial condition, results of operations and prospects may have changed since that date.
The
information incorporated by reference or provided in this prospectus contains estimates and other statistical data made by independent
parties and by us relating to market size and growth and other data about our industry. We obtained the industry and market data in this
prospectus from our own research as well as from industry and general publications, surveys and studies conducted by third parties. This
data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the industries
in which we operate that are subject to a high degree of uncertainty, including those discussed in “Risk Factors.” We caution
you not to give undue weight to such projections, assumptions, and estimates. Further, industry and general publications, studies and
surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy
or completeness of such information. While we believe that these publications, studies, and surveys are reliable, we have not independently
verified the data contained in them. In addition, while we believe that the results and estimates from our internal research are reliable,
such results and estimates have not been verified by any independent source.
For
investors outside the United States (“U.S.”): We and the placement agent have not done anything that would permit
this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other
than in the U.S. Persons outside the U.S. who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the securities and the distribution of this prospectus outside of the U.S.
PROSPECTUS
SUMMARY
The
following information is a summary of the prospectus and does not contain all of the information you should consider before investing
in our common stock. You should read the entire prospectus carefully, including the matters set forth under “Risk Factors,”
“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our consolidated financial
statements and the notes relating to the consolidated financial statements, included elsewhere in this prospectus. Unless the context
requires otherwise, references to “Aridis,” “Company,” “we,” “us” or “our”
refer to Aridis Pharmaceuticals, Inc., a Delaware corporation and its subsidiaries.
Overview
We
are a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal
antibodies, or mAbs, to treat life-threatening infections. mAbs represent a fundamentally new treatment approach in the infectious disease
market and are designed to overcome key issues associated with current therapies, including drug resistance, short duration of response,
tolerability, negative impact on the human microbiome, and lack of differentiation between treatment alternatives. Our proprietary product
pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections,
primarily hospital-acquired pneumonia, or HAP, ventilator-associated pneumonia, or VAP and cystic fibrosis. Our clinical stage product
candidates have exhibited promising preclinical data and clinical data. Our lead product candidates, AR-301 and AR-320, target the alpha
toxin produced by gram-positive bacteria Staphylococcus aureus, or S. aureus, a common pathogen associated with HAP and
VAP. AR-501 is a broad spectrum small molecule anti-infective we are developing in addition to our targeted mAb product candidates.
The
majority of candidates from our product pipeline are derived by employing our differentiated antibody discovery platform called MabIgXTM
and λPEXTM. This platform is designed to comprehensively screen the B-cell repertoire and isolate human antibody-producing
B-cells from individuals who have either successfully overcome an infection by a particular pathogen or have been vaccinated against
a particular pathogen. We believe that B-cells from these patients are the ideal source of highly protective and efficacious mAbs which
can been administered safely to other patients. λPEXTM complements and further extends the capabilities of MabIgX to
quickly screen large number of antibody producing B-cells from patients and generation of high mAb producing mammalian production cell
line at a speed not previously attainable. As a result, we can significantly reduce time for antibody discovery and manufacturing compared
to conventional approaches.
Two
of our mAbs in advanced clinical development are being developed for treatment of HAP and VAP in intensive care units or ICUs. Our initial
clinical indication for AR-301 is for adjunctive therapeutic treatment with standard of care, or SOC, antibiotics for HAP and VAP. AR-320
is being developed as a pre-emptive treatment of mortality and morbidity associated with HAP and VAP. Current SOC antibiotics used to
treat HAP and VAP typically involve a combination of several broad-spectrum antibiotics that are prescribed empirically at the start
of treatment. The specific empirical antibiotic regimens that are prescribed vary widely among physicians, and generally result in modest
clinical benefits due to a number of reasons, which can include an infection by an antibiotic resistant strain, immune deficiency, or
potential mismatch of the antibiotics regimen to the etiologic agent. Recently, rapid diagnostic tests have been introduced that allow
the identification of infection-causing agents within hours. These increasingly common rapid tests allow physicians to prescribe a more
appropriate antibiotics regimen, and eventually more targeted anti-infectives such as AR-301 and AR-320 earlier in the course of infection.
This evidenced-based treatment approach is designed to remove issues associated with empirical broad-spectrum antibiotics such as inappropriate
antibiotic selection and promotion of antibiotic resistance. In contrast to the lack of differentiation among SOC antibiotics, mAbs are
highly differentiated from SOC antibiotics in mechanism of action, pharmacokinetic and pharmacodynamic profile, and thus are well suited
to complement antibiotics when used together. As an adjunctive treatment, AR-301 has the potential to improve the effectiveness of SOC
antibiotics and cover antibiotic resistant S. aureus strains, while not competing directly with antibiotics. To emphasize the
benefits of our product candidates as an adjunctive therapy, we design clinical trials based on superiority endpoints.
AR-301
and AR-320 neutralize alpha-toxin from Staphylococcus aureus bacteria, leading to protection from alpha-toxin mediated
destruction of host cells, including cells from the immune system. This mode of action is independent of the antibiotic resistance
profile of S. aureus, and as such AR-301 and AR-320 are active against infections caused by both MRSA (methicillin-resistant staphylococcus
aureus) and MSSA (methicillin-sensitive staphylococcus aureus). AR-320 and AR-301 are complementary products. AR-320
treatment focuses on preventive treatment of S. aureus pneumonia, which complements Aridis’ AR-301 Phase 3 mAb program
that is being developed as a therapeutic treatment of S. aureus pneumonia. We believe that AR-301 will be first-line
treatment, first to market, first-in-class pre-emptive treatment of S. aureus colonized patients. The same first-line, first
to market and first-in-class strategy applies to the acute treatment with the monoclonal antibody AR-320. As these programs are
in the final stages of clinical development before licensure, we are giving significant consideration to partnering or entering into
strategic transactions with larger pharmaceutical companies.
On
March 20, 2023, we received written notice from MedImmune Limited (“MedImmune”) that it has terminated that certain License
Agreement by and between MedImmune and us dated as of July 12, 2021, and as amended by Amendment No. 1 to License Agreement, dated as
of August 9, 2021 (the “License Agreement”), pursuant to Section 9.2.1 of the License Agreement for non-payment of the Upfront
Cash Payment which was due on December 31, 2021. The notice states that such termination shall be effective on March 30, 2023. As a result
of the termination notice, the on-going AR-320-003 Phase 3 clinical study has been put on hold. We do not agree that we are in material
breach of the License Agreement. Based on the failure of MedImmune to assist in the necessary technology transfer pursuant to Section
3.5.2 of the License Agreement, we notified MedImmune on March 24, 2023 that it was in material breach of Section 3.5.2 and requested
that the material breach be cured as soon as possible. We are in active discussions to resolve the matter to the mutual interests
of both parties.
AR-320
is being developed for pre-emptive treatment of high-risk patients under 65 years old for prevention of nosocomial pneumonia caused by
S. aureus, which is associated with significant morbidity and mortality despite current standard of care, including antibiotics
and infection control practices like ventilator-associated pneumonia (VAP) bundles. Currently, there are no treatments available for
prevention or early preemptive management of patients at high-risk of developing S. aureus pneumonia. AR-320 has the potential
to address this unmet medical need by reducing the incidence of S. aureus pneumonia in patients at high-risk of developing the
disease, e.g., mechanically ventilated patients in the intensive care unit (ICU) who are colonized with S. aureus in their respiratory
tract.
HAP
and VAP pose serious challenges in the hospital setting, as SOC antibiotics are becoming inadequate in treating infected patients. There
are approximately 3,000,000 cases of pneumonia reported in the U.S. per year and approximately 628,000 annual cases of HAP and VAP caused
by gram negative bacteria and MRSA (DRG, 2016). These patients are typically at high risk of mortality, which is compounded by other
life-threatening co-morbidities and the rise in antibiotic resistance. Epidemiology studies estimate that the probability of death attributed
to S. aureus ranges from 29% to 55%. In addition, pneumonia infections can prolong patient stays in ICUs and the use of mechanical
ventilation, creating a major economic burden on patients, hospital systems and payors. For example, ICU cost of care for a ventilated
pneumonia patient is approximately $10,000 per day in the U.S., and the duration of ICU stays are typically twice that of a non-ventilated
patient (Infection Control and Hospital Epidemiology. 2010, vol. 31, pp. 509-515). The average cost of care per pneumonia patient is
approximately $41,250 which increases 86% for HAP/VAP patients to approximately $76,730. We estimate that our two clinical mAb candidates
have an addressable market of $25 billion and the potential to address approximately 325,000 HAP and VAP patients in the U.S.
Recent Developments
Our cash and cash equivalents were approximately $50,000 as of July
15, 2023. We will need to obtain financing in order to continue to fund our operations on or before July 31, 2023. Any failure or
delay to secure such financing could force us to delay, limit or terminate our operations, make reductions in our workforce, liquidate
all or a portion of our assets and/or seek protection under Chapters 7 or 11 of the United States Bankruptcy Code. There can be no assurance
that our implementation of these contingency plans will not have a material adverse effect on our business. This offering is being made
on a best efforts basis and we may sell fewer than all of the securities offered hereby and may receive significantly less in net proceeds
from this offering.
If the net proceeds from this offering are $1.6 million (assuming
an offering with gross proceeds of $2,000,000), we believe we will be able to fund our operations until September 2023
under our current business plan. If the net proceeds from this offering are $664,000 (assuming an offering with gross proceeds
of $1,000,000), we believe we will be able to fund our operations until mid-August 2023 under our current business plan.
Potential income such as income from on-going pharma partnering discussions and future financings
are not included in the projections.
On
July 17, 2023, we received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) that it
would delist our shares of common stock from the Nasdaq Capital Market upon the opening of trading on July 19, 2023. As of July 19, 2023,
our common stock began trading on the OTC Markets Pink Sheets.
Pursuant
to Section 4(ii) of the Note Purchase Agreement (the “Note Agreement”) dated as of November 23, 2021 between us and
Streeterville Capital, LLC (“Streeterville”), we covenanted that until all of our obligation under the notes issued pursuant to the Note Agreement are paid and
performed in full, our common stock would be
listed or quoted for trading on any of (a) NYSE, (b) NASDAQ, (c) OTCQX, or (d) OTCQB. As a result of the delisting from Nasdaq and
our common stock trading on the OTC Markets Pink Sheets, the covenant has been breached. Pursuant to Section 4.1(l) of Secured
Promissory Note #1 dated November 23, 2021 with Streeterville, an Event of Default has occurred as a result of our failing to
observe or perform any covenant set forth in Section 4 of the Note Agreement.
In
addition, pursuant to Sections 4(ii) and 4(iii) of the Note Purchase and Loan Restructuring Agreement dated as of April 26, 2023 (the
“Note Purchase Agreement”), we covenanted that until all of our obligations under the notes issued pursuant to the Note Purchase
Agreement, our common stock shall be listed or quoted for trading on either of (a) NYSE, or (b) NASDAQ and trading in our common stock
will not be suspended, halted, chilled, frozen, reach zero bid or otherwise cease trading on our principal trading market. As a result
of the delisting from Nasdaq and our common stock trading on the OTC Markets Pink Sheets, a Triggering Event (as defined in the April
2023 Note) has occurred pursuant to Section 4.1(h) of the Secured Promissory Note dated April 26, 2023 (the “April 2023 Note”)
and if not cured within 5 trading days will automatically result in an Event of Default.
On
July 20, 2023, Streeterville provided a waiver with respect to the breach of Section 4(ii) of that certain Note Purchase Agreement dated
November 23, 2021, in connection with the recent delisting of the Company’s common stock from Nasdaq to OTC Markets Pink Sheets.
This in turn means that no such Event of Default has occurred pursuant to Section 4.1(l) of Secured Promissory Note #1 dated November
23, 2021, with respect to the recent delisting.
Additionally,
Streeterville provided a waiver with respect to the breach of Section 4(ii) and 4(iii) of that certain Note Purchase and Loan Restructuring
Agreement dated April 26, 2023, in connection with the recent delisting of our common stock from Nasdaq to OTC Markets Pink Sheets. This
in turn means that no such Triggering Event has occurred pursuant to Section 4.1(h) of Secured Promissory Note dated April 26, 2023,
with respect to the recent delisting.
These
are one-time waivers with respect to the recent delisting of our common stock and are not waivers with respect to any other
event.
Corporate
Information
We
were formed under the name “Aridis, LLC” in the State of California on April 24, 2003 as a limited liability company. On
August 30, 2004, we changed our name to “Aridis Pharmaceuticals, LLC.” On May 21, 2014, we converted into a Delaware corporation
named “Aridis Pharmaceuticals, Inc.” Our fiscal year end is December 31. Our principal executive offices are located at 983
University Avenue, Building B, Los Gatos , California 95032. Our telephone number is (408) 385-1742. Our website address is www.aridispharma.com.
The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website
address in this prospectus solely as an inactive textual reference.
We
have proprietary rights to a number of trademarks used in this prospectus which are important to our business. Solely for convenience,
the trademarks and trade names in this prospectus are referred to without the ® and TM symbols, but such references should
not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights
thereto. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners.
Implications
of Being an Emerging Growth Company
As
a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an emerging growth company as defined
in the Jumpstart Our Business Startups Act (“JOBS Act”) enacted in 2012. As an emerging growth company, we expect to take
advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not
limited to:
|
● |
being
permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements,
with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
disclosure in this prospectus; |
|
|
|
|
● |
not
being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley
Act”); |
|
|
|
|
● |
reduced
disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and |
|
|
|
|
● |
exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. |
We
may use these provisions until the last day of our fiscal year following the fifth anniversary of the completion of our initial public
offering. However, if certain events occur prior to the end of such five-year period, including if we become a “large accelerated
filer,” our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year
period, we will cease to be an emerging growth company prior to the end of such five-year period.
The
JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. As an emerging growth company, we intend to take advantage of an extended transition period for complying with
new or revised accounting standards as permitted by The JOBS Act.
To
the extent that we continue to qualify as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the
Securities Exchange Act of 1934, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as
an emerging growth company may continue to be available to us as a smaller reporting company, including: (i) not being required to comply
with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (ii) scaled executive compensation disclosures;
and (iii) the requirement to provide only two years of audited financial statements, instead of three years.
THE
OFFERING
Securities
we are offering |
|
Up
to 9,090,909 shares of common stock and 9,090,909 warrants to purchase up to
9,090,909 shares of common stock, or pre-funded warrants to purchase shares of common
stock and common warrants to purchase shares of common stock. The shares of common stock
or pre-funded warrants, respectively, and common warrants are immediately separable and will
be issued separately in this offering, but must initially be purchased together in this offering.
Each common warrant has an exercise price of $___ per share of common stock and is exercisable
on the issuance date of the common warrants and will expire five years from the issuance
date of the common warrants. We are also registering the shares of common stock issuable
upon exercise of the pre-funded warrants and the common warrants pursuant to this prospectus. |
|
|
|
Pre-funded
warrants offered by us |
|
We
are also offering to each purchaser whose purchase of shares in this offering would otherwise result in the purchaser, together with
its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of
our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if the purchaser
so chooses, pre-funded warrants (each pre-funded warrant to purchase one share of our common stock) in lieu of shares that would
otherwise result in the purchaser’s beneficial ownership exceeding 4.99% of our outstanding common stock (or, at the election
of the purchaser, 9.99%). The purchase price of each pre-funded warrant and accompanying common warrant will equal the price at which
one share of common stock and accompanying common warrant are being sold to the public in this offering, minus $0.0001,
and the exercise price of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will be exercisable
immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. For each pre-funded warrant
we sell, the number of shares we are offering will be decreased on a one-for-one basis. See “Description of Securities We Are
Offering” for additional information. |
|
|
|
Terms
of the offering |
|
This
offering will terminate on August 4, 2023, unless we decide to terminate the offering (which we may do at any time in our
discretion) prior to that date. |
Common
stock outstanding prior to this offering |
|
36,213,
952 shares of common
stock. |
|
|
|
Common
stock outstanding after this offering |
|
45,304,861
shares, assuming no
sale of pre-funded warrants, which, if sold, would reduce the number of shares of common stock that we are offering on a one-for-one
basis, and no exercise of the common warrants issued in this offering. |
|
|
|
Use
of proceeds |
|
We
estimate that the net proceeds from this offering will be approximately $1.6 million, based on an assumed public offering
price of $0.22 per share, which was the last reported sale price of our common stock on July 24, 2023 on the
OTC Markets Pink Sheets and an assumed offering amount of $2,000,000 in gross proceeds, after deducting the placement agent
fees and estimated offering expenses payable by us. We intend to use the net proceeds to fund our planned clinical trials, manufacturing
and process development, analytical testing, regulatory expenses and for general corporate purposes, including working capital and
repaying a portion of certain secured promissory notes (the “Notes”) held by Streeterville in the event we do not negotiate
a deferral of payment from Streeterville. Beginning in August 2023, we will be required to repay $495,000 on Note 1 on a monthly
basis and beginning in October 2023, 16.667% of the outstanding balance on Note 2 monthly. See “Use of Proceeds” for
a more complete description of the intended use of proceeds from this offering. |
|
|
|
Risk
Factors |
|
You
should read the “Risk Factors” section starting on page 6 for a discussion of factors to consider carefully before
deciding to invest in our securities. |
|
|
|
OTC
Pink symbol |
|
“ARDS.”
There is no established public trading market for the common warrants or pre-funded warrants
, and we do not expect such a market to develop. We do not intend to list the common warrants or pre-funded warrants on any securities
exchange or other trading market. Without an active trading market, the liquidity of the pre-funded warrants and the warrants will
be extremely limited. |
The
number of shares of our common stock that will be outstanding after this offering is based on 36,213,952 shares of our common
stock outstanding as of July 12, 2023, and excludes:
|
● |
2,330,576
shares of our common stock issuable upon the
exercise of options to purchase shares of our common stock outstanding as of July 12, 2023, with a weighted-average exercise price
of $6.18 per share; |
|
|
|
|
● |
10,742,404
shares of our common stock issuable upon the exercise of warrants to purchase common stock outstanding as of July 12, 2023,
with a weighted-average exercise price of $1.23 per share; |
|
|
|
|
● |
182,120 shares of our common stock issuable upon the
vesting of restricted stock units outstanding as of July 12, 2023; and |
|
|
|
|
● |
234,442
shares of our common stock reserved for future
issuance under our stock incentive plans. |
|
|
|
|
● |
Unless
expressly indicated or the context requires otherwise, all information in this prospectus assumes no (i) no purchaser elects to purchase
pre-funded warrants and (ii) no exercise of the common warrants offered hereby. |
RISK
FACTORS
An
investment in our common stock involves a high degree of risk. You should give careful consideration to the following risk factors, in
addition to the other information included in this prospectus, including our financial statements and related notes, before deciding
whether to invest in shares of our common stock. The occurrence of any of the adverse developments described in the following risk factors
could materially and adversely harm our business, financial condition, results of operations or prospects. In that case, the trading
price of our common stock could decline, and you may lose all or part of your investment.
Risks
Relating to Our Financial Position and Need for Additional Capital
We
expect to continue to incur increasing net losses for the foreseeable future, and we may never achieve or maintain profitability.
We
are a late-stage biopharmaceutical company with a limited operating history. Investment in biopharmaceutical product development
is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate
will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We
have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur
significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have
incurred losses in each period since our inception. For the year ended December 31, 2022 and the three months ended March 31, 2023, we
reported a net loss of approximately $30.4 million and $6.8 million, respectively. As of December 31, 2022 and March 31, 2023, we had
an accumulated deficit of $195.7 million and $202.5 million, respectively.
To
become and remain profitable, we or our partners must succeed in developing our product candidates, obtaining regulatory approval for
them, and manufacturing, marketing and selling those products for which we or our partners may obtain regulatory approval. We or they
may not succeed in these activities, and we may never generate revenue from product sales that is significant enough to achieve profitability.
Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable
to accurately predict the timing or amount of future expenses or when, or if, we will be able to achieve or maintain profitability. Currently,
we have no products approved for commercial sale, and to date we have not generated any product revenue. We have financed our operations
primarily through the sale of equity securities, upfront payments pursuant to collaboration and license agreements, government grants,
debt and capital lease and equipment financing. The size of our future net losses will depend, in part, on the rate of growth or contraction
of our expenses and the level and rate of growth, if any, of our revenues. Our ability to achieve profitability is dependent on our ability,
alone or with others, to complete the development of our products successfully, obtain the required regulatory approvals, manufacture
and market our proposed products successfully or have such products manufactured and marketed by others, and gain market acceptance for
such products. There can be no assurance as to whether or when we will achieve profitability.
The
report of our independent registered public accounting firm on our consolidated
financial statements as of and for the year ended December 31, 2022 includes an explanatory paragraph that expresses substantial
doubt about our ability to continue as a going concern, indicating the possibility that we may not be able to operate in the future.
Primarily
as a result of our losses incurred to date, our expected continued future losses, and limited cash balances, we have included disclosure
in our consolidated financial statements expressing substantial doubt about our ability to continue as a going concern. We do not have
sufficient cash on hand and available liquidity to meet our obligations through the twelve months following the date the consolidated
financial statements are issued. Our cash and cash equivalents were approximately $50,000 as of July 15, 2023. We will need to obtain
financing in order to fund our operations on or before July 31, 2023. Our ability to continue as a going concern is contingent upon,
among other factors, the sale of the shares of our common stock or obtaining alternate financing. Any failure or delay to secure such
financing could force us to delay, limit or terminate our operations, make reductions in our workforce, liquidate all or a portion of
our assets and/or seek protection (“Bankruptcy Protection”) under Chapters 7 or 11 of the United States Bankruptcy Code.
If the net proceeds from this offering are $1.6 million (assuming an offering with gross proceeds of $2,000,000), we believe
we will be able to fund our operations until September 2023 under our current business plan. If the net proceeds from this offering
are $664,000 (assuming an offering with gross proceeds of $1,000,000), we believe we will be able to fund our operations
until mid-August 2023 under the current business plan. Potential income such income from on-going pharma partnering discussions
and future financings are not included in the projections.
In
the event we pursue Bankruptcy Protection, we will be subject to the risks and uncertainties associated with such proceedings.
In
the event we file for relief under the United States Bankruptcy Code, our operations, our ability to develop and execute our business
plan and our continuation as a going concern will be subject to the risks and uncertainties associated with bankruptcy proceedings, including,
among others: our ability to execute, confirm and consummate a plan of reorganization; the additional, significant costs of bankruptcy
proceedings and related fees; our ability to obtain sufficient financing to allow us to emerge from bankruptcy and execute our business
plan post-emergence, and our ability to comply with terms and conditions of that financing; our ability to continue our operations in
the ordinary course; our ability to maintain our relationships with our consumers, business partners, counterparties, employees and other
third parties; our ability to obtain, maintain or renew contracts that are critical to our operations on reasonably acceptable terms
and conditions; our ability to attract, motivate and retain key employees; the ability of third parties to use certain limited safe harbor
provisions of the United States Bankruptcy Code to terminate contracts without first seeking Bankruptcy Court approval; the ability of
third parties to force us to into Chapter 7 proceedings rather than Chapter 11 proceedings and the actions and decisions of our stakeholders
and other third parties who have interests in our bankruptcy proceedings that may be inconsistent with our operational and strategic
plans. Any delays in our bankruptcy proceedings would increase the risks of our being unable to reorganize our business and emerge from
bankruptcy proceedings and may increase our costs associated with the bankruptcy process or result in prolonged operational disruption
for us. Also, we would need the prior approval of the bankruptcy court for transactions outside the ordinary course of business during
the course of any bankruptcy proceedings, which may limit our ability to respond timely to certain events or take advantage of certain
opportunities. Because of the risks and uncertainties associated with any bankruptcy proceedings, we cannot accurately predict or quantify
the ultimate impact of events that could occur during any such proceedings. There can be no guarantees that if we seek Bankruptcy Protection
we will emerge from Bankruptcy Protection as a going concern or that holders of our common stock will receive any recovery from any bankruptcy
proceedings.
In
the event we are unable to pursue Bankruptcy Protection under Chapter 11 of the United States Bankruptcy Code, or, if pursued, successfully
emerge from such proceedings, it may be necessary to pursue Bankruptcy Protection under Chapter 7 of the United States Bankruptcy Code
for all or a part of our businesses.
In
the event we are unable to pursue Bankruptcy Protection under Chapter 11 of the United States Bankruptcy Code, or, if pursued, successfully
emerge from such proceedings, it may be necessary for us to pursue Bankruptcy Protection under Chapter 7 of the United States Bankruptcy
Code for all or a part of our businesses. In such event, a Chapter 7 trustee would be appointed or elected to liquidate our assets for
distribution in accordance with the priorities established by the United States Bankruptcy Code. We believe that liquidation under Chapter
7 would result in significantly smaller distributions being made to our stakeholders than those we might obtain under Chapter 11 primarily
because of the likelihood that the assets would have to be sold or otherwise disposed of in a distressed fashion over a short period
of time rather than in a controlled manner and as a going concern.
Our obligations
to Streeterville are secured by a security interest in all of our assets, so if we default on those obligations, Streeterville could
foreclose on our assets.
Our
obligations under the Notes issued to Streeterville are secured by a first-position security interest in all right, title, interest,
claims and demands of us in and to the property as provided in the Security Agreement, dated April 26, 2023 between us and
Streeterville. As of June 30, 2023, approximately $11.0 million was owed to Streeterville under the Notes including accrued
interest. Beginning in August 2023, we will be required to repay $495,000 on Note 1 on a monthly basis and beginning in
October 2023 we will be required to pay 16.667% of the outstanding balance on Note 2 monthly. The maturity date of the Notes are
November 2023 and April 2024. If we default on our obligations under these agreements, Streeterville could foreclose on its security
interests and liquidate some or all of these assets, which would harm our financial condition and results of operations and would
require us to reduce or cease operations and possibly seek Bankruptcy Protection.
We
will require substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease
operations.
Developing
pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. Development of our product candidates
will require substantial additional funds to conduct research, development and clinical trials necessary to bring such product candidates
to market and to establish manufacturing, marketing and distribution capabilities. We expect our development expenses to substantially
increase in connection with our ongoing activities, particularly as we advance our clinical programs. Our future capital requirements
will depend on many factors, including, among others:
|
● |
the
scope, rate of progress, results and costs of our preclinical and non-clinical studies, clinical trials and other research and development
activities; |
|
|
|
|
● |
the
scope, rate of progress and costs of our manufacturing development and commercial manufacturing activities; |
|
|
|
|
● |
the
cost, timing and outcomes of regulatory proceedings, including FDA review of any Biologics License Application, or BLA, or New Drug
Application, or NDA, that we file; |
|
|
|
|
● |
payments
required with respect to development milestones we achieve under our in-licensing agreements, including any such payments to University
of Chicago, University of Iowa, Brigham and Women’s Hospital, Inc., Brigham Young University, Public Health Service and Kenta
Biotech Ltd., Massachusetts Institute of Technology-Broad Institute, University of Alabama at Birmingham Research Foundation, and
Medimmune Ltd.; |
|
|
|
|
● |
the
costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims; |
|
|
|
|
● |
the
costs associated with commercializing our product candidates if they receive regulatory approval; |
|
|
|
|
● |
the
cost and timing of establishing sales and marketing capabilities; |
|
● |
competing
technological efforts and market developments; |
|
|
|
|
● |
changes
in our existing research relationships; |
|
|
|
|
● |
our
ability to establish collaborative arrangements to the extent necessary; |
|
|
|
|
● |
revenues
received from any future products; |
|
|
|
|
● |
the
ability to achieve and receive milestone payments for products licensed to collaborators; and |
|
|
|
|
● |
payments
received under any future strategic collaborations. |
We
anticipate that we will continue to generate significant losses for the next several years as we incur expenses to complete our clinical
trial programs for our product candidates, build commercial capabilities, develop our pipeline and expand our corporate infrastructure.
There is a risk of delay or failure at any stage of developing a product candidate, and the time required and costs involved in successfully
accomplishing our objectives cannot be accurately predicted. Actual drug research and development costs could substantially exceed budgeted
amounts, which could force us to delay, reduce the scope of or eliminate one or more of our research or development programs. Additionally,
if the Cystic Fibrosis Foundation does not continue to provide funding support, we may not be able to complete the Phase 1/2a clinical
trial relating to AR-501. Furthermore, if the European Commission’s IMI (Innovative Medicines Initiative) does not continue to
provide support, we may not be able to complete the Phase 3 clinical trial relating to AR-320.
We
may never be able to generate a sufficient amount of product revenue to cover our expenses. Until we do, we expect to seek additional
funding through public or private equity or debt financings, collaborative relationships, license agreements, capital lease transactions
or other available financing transactions. However, there can be no assurance that additional financing will be available on acceptable
terms, if at all, and such financings could be dilutive to existing security holders. Moreover, in the event that additional funds are
obtained through arrangements with collaborators, such arrangements may require us to relinquish rights to certain of our technologies,
product candidates or products that we would otherwise seek to develop or commercialize ourselves.
If
adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development
programs. Our failure to obtain adequate financing when needed and on acceptable terms would have a material adverse effect on our business,
financial condition and results of operations.
If
we cannot meet requirements under our license and sublicense agreements, we could lose the rights to our products, which could have a
material adverse effect on our business.
We
depend on licensing and sublicensing agreements with third parties such as the University of Chicago, University of Iowa, Brigham and
Women’s Hospital, Inc., Brigham Young University, Public Health Service, Kenta Biotech Ltd., Massachusetts Institute of Technology-Broad
Institute, University of Alabama at Birmingham Research Foundation, and Medimmune Ltd. to maintain the intellectual property rights to
certain of our product candidates. These agreements require us to make payments and satisfy performance obligations in order to maintain
our rights under these agreements. All of these agreements last either throughout the life of the patents that are the subject of the
agreements, or with respect to other licensed technology, for a number of years after the first commercial sale of the relevant product.
If we fail to comply with the obligations under our license agreements or use the intellectual property licensed to us in an unauthorized
manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreements are
terminated, we may not be able to develop, manufacture, market or sell the products covered by our agreements and those being tested
or approved in combination with such products. Such an occurrence could materially adversely affect the value of the product candidate
being developed under any such agreement and any other product candidates being developed or tested in combination.
In
addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents
licensed to us. If we do not meet our obligations under our license agreements in a timely manner, or use the intellectual property licensed
to us in an unauthorized manner, we could be required to pay damages and we could lose the rights to our proprietary technology if our
licensor terminated the license. If our license agreements are terminated, we may not be able to develop, manufacture, market or sell
the products covered by our agreements and any being tested or approved in combination with such products. Such an occurrence could have
a material adverse effect on our business, results of operations and financial condition.
Our
license agreement with MedImmune may no longer be effective as a result of MedImmune’s termination
notice.
On
March 20, 2023, we received written notice from MedImmune that it has terminated that certain License Agreement pursuant to Section 9.2.1
of the License Agreement for non-payment of the Upfront Cash Payment which was due on December 31, 2021. Such termination was effective
as of March 30, 2023. As a result of the termination notice, the on-going AR-320-003 Phase 3 clinical study has been put on hold. We
do not agree that we are in material breach of the License Agreement. In the event the License Agreement is no longer effective, all
rights and licenses granted by MedImmune pursuant to the License Agreement would terminate and we would be required pursuant to the License
Agreement to take certain actions to return intellectual property and drug product to MedImmune. The termination of the AR-320 program
pursuant to any termination of the License Agreement may have a material adverse effect on our business, financial condition and results
of operations.
The
delayed filing of some of our periodic SEC reports has made us currently ineligible to use a registration statement on Form S-3 to register
the offer and sale of securities, which could adversely affect our ability to raise future capital.
As
a result of the delayed filing of some of our periodic reports with the SEC, we are not currently eligible to register the offer and
sale of our securities using a registration statement on Form S-3. To regain eligibility to use Form S-3, we must be timely and current
in our public reporting for a period of 12 months preceding our intended S-3 filing. Should we wish to register the offer and sale of
our securities to the public prior to the time we are eligible to use Form S-3, both our transaction costs and the amount of time required
to complete the transaction could increase, making it more difficult to execute any such transaction successfully and potentially harming
our financial condition.
Risks
Relating to Clinical Development and Commercialization of Our Product Candidates
If
we fail to successfully complete clinical trials, fail to obtain regulatory approval or fail to successfully commercialize our product
candidates, our business would be harmed and the value of our securities would decline.
We
must be evaluated in light of the uncertainties and complexities affecting a pre-commercial biopharmaceutical company. We have not completed
clinical development for any of our product candidates. Our five lead product candidates are AR-301, AR320, AR-501 and AR-101, and AR-701.
We initiated a Phase 3 pivotal trial of AR-301 in VAP patients, AR-501 is in Phase 1/2a clinical testing and AR-101 is ready for Phase
2/3 pivotal testing. The Phase 3 clinical trial evaluating AR-320 for the prevention of VAP has been put on hold. We cannot be assured
that our planned clinical development for our product candidates will be completed in a timely manner, or at all, or that we, or any
future partner, will be able to obtain approval for our product candidates from the FDA or any foreign regulatory authority.
Regulatory
agencies, including the FDA must approve our product candidates before they can be marketed or sold. The approval process is lengthy,
requires significant capital expenditures, and is uncertain as to outcome. Our ability to obtain regulatory approval of any product candidate
depends on, among other things, completion of additional clinical trials, whether our clinical trials demonstrate statistically significant
efficacy with safety issues that do not potentially outweigh the therapeutic benefit of the product candidates, and whether the regulatory
agencies agree that the data from our future clinical trials are sufficient to support approval for any of our product candidates. The
final results of our current and future clinical trials may not meet FDA or other regulatory agencies’ requirements to approve
a product candidate for marketing, and the regulatory agencies may otherwise determine that our manufacturing processes or facilities
are insufficient to support approval. We, and our current and potential future collaborators, may need to conduct more clinical trials
than we currently anticipate. Even if we do receive FDA or other regulatory agency approval, we or our collaborators may not be successful
in commercializing approved product candidates. If any of these events occur, our business could be materially harmed and the value of
our securities would decline.
We,
or our collaborators, may face delays in completing our clinical trials, and may not be able to complete them at all.
Clinical
trials necessary to support an application for approval to market any of our product candidates have not been completed. Our, or our
collaborators,’ current and future clinical trials may be delayed, unsuccessful, or terminated as a result of many factors, including,
but not limited to:
|
● |
delays
in reaching agreement on trial design and clinical study protocol with investigators and regulatory authorities in various countries
where our clinical trials are being conducted; |
|
|
|
|
● |
governmental
or regulatory delays, failure to obtain regulatory approval or changes in regulatory requirements, policy or guidelines; |
|
|
|
|
● |
adding
new clinical trial sites; |
|
|
|
|
● |
reaching
agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; |
|
|
|
|
● |
the
actual performance of CROs and clinical trial sites in ensuring the proper and timely conduct of our clinical trials; |
|
|
|
|
● |
developing
and validating companion diagnostics on a timely basis; |
|
|
|
|
● |
adverse
effects experienced by subjects in clinical trials; |
|
|
|
|
● |
manufacturing
sufficient quantities of product candidates for use in clinical trials; |
|
● |
delay
or failure in achieving study efficacy endpoints and completing data analysis for a trial; |
|
|
|
|
● |
regulators
or institutional review boards, or IRBs, may not authorize us to commence a clinical trial; |
|
|
|
|
● |
regulators
or IRBs may suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or concerns
about patient safety; |
|
|
|
|
● |
we
may suspend or terminate our clinical trials if we believe that they expose the participating patients to unacceptable health risks; |
|
|
|
|
● |
patients
may not complete clinical trials due to safety issues, side effects, such as injection site discomfort, a belief that they are receiving
placebo instead of our product candidates, or other reasons; |
|
|
|
|
● |
patients
with serious diseases included in our clinical trials may die or suffer other adverse medical events for reasons that may not be
related to our product candidates; |
|
|
|
|
● |
in
those trials where our product candidate is being tested in combination with one or more other therapies, deaths may occur that may
be attributable to the other therapies; |
|
|
|
|
● |
we
may have difficulty in maintaining contact with patients after treatment, preventing us from collecting the data required by our
study protocol; |
|
|
|
|
● |
product
candidates may demonstrate a lack of efficacy during clinical trials; |
|
|
|
|
● |
personnel
conducting clinical trials may fail to properly administer our product candidates; |
|
|
|
|
● |
COVID-19
pandemic may be protracted and cause a significant decline in patient enrollment rate; and |
|
|
|
|
● |
our
collaborators may decide not to pursue further clinical trials. |
In
addition, we rely on academic institutions, medical institutions, physician practices and CROs to conduct, supervise or monitor some
or all aspects of clinical trials involving our product candidates. We have less control over the timing and other aspects of these clinical
trials than if we conducted the monitoring and supervision entirely on our own. Third parties may not perform their responsibilities
for our clinical trials on our anticipated schedule or consistent with a clinical trial protocol or applicable regulations. We also may
rely on CROs to perform our data management and analysis. They may not provide these services as required or in a timely or compliant
manner, and we may be held legally responsible for any or all of their performance failures or inadequacies.
If
we or our collaborators experience delays in the completion of, or termination of, any clinical trial of our product candidates, the
commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product
candidates will be delayed or eliminated. In addition, any delays in completing our clinical trials will increase our costs, slow our
product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of
these occurrences may harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to,
a delay in the commencement or completion of clinical trials may also lead to the denial of regulatory approval of our product candidates.
Our
development of a COVID-19 therapeutic candidate is at an early stage and we may not be able to successfully develop an effective therapeutic
to treat COVID-19 in a timely manner, if at all.
Various
government entities, including the U.S. government, are offering incentives, grants, and contracts to encourage additional investment
by commercial organizations into preventative and therapeutic agents against COVID-19, and this may have the effect of increasing the
number of competitors and/or providing advantages to known competitors. We are aware of a substantial number of companies, individuals
and institutions working to develop a treatment for COVID-19, many of which have substantially greater financial, scientific, and other
resources than us, and another party may be successful in producing an effective treatment against COVID-19 before we do. The rapid expansion
of development programs directed at COVID-19 may also generate a scarcity of manufacturing capacity among contract research organizations
that provide cGMP materials for development and commercialization of biopharmaceutical products.
We
are currently unable to commit adequate financial resources to the development of a monoclonal antibody treatment for COVID-19, which
may cause delays in or otherwise negatively impact our other development programs. Similarly resources committed to other development
programs may negatively impact the financial resources available for our COVID-19 therapeutic development. In addition, our management
and scientific teams have dedicated substantial efforts to our COVID-19 therapeutic development. As of the date of this report, we have
26 employees, which may make us more reliant on our individual employees and on outside contractors than companies with a greater number
of employees. If we fail to attract and retain management and scientific personnel, we may be unable to successfully produce, develop
and commercialize our therapeutic candidates.
In
addition, any success in preclinical testing we might observe for our COVID-19 therapeutic candidate may not be predictive of the results
of later-stage human clinical trials. Factors such as safety, efficacy and adverse events can emerge at any time in clinical testing
and have the potential to have adverse consequences for our ability to proceed with clinical trials. Other factors such as the emergence
of new SARS-CoV-2 mutant virus variants rendering a reduction or complete loss of binding or neutralization by the mAbs, manufacturing
challenges, availability of raw materials, and slow-downs in the global supply chain may delay or prevent us from receiving regulatory
approval of our therapeutic candidate or, if we do receive regulatory approval, prevent a successful product launch. We may not be successful
in developing a therapeutic, or another party may be successful in producing a more efficacious vaccine or other treatment for COVID-19.
If
we encounter difficulties enrolling patients in our clinical trials, our clinical trials could be delayed or otherwise adversely affected.
Clinical
trials for our product candidates require us to identify and enroll a large number of patients with the disease under investigation.
We may not be able to enroll a sufficient number of patients with required or desired characteristics to conduct our clinical trials
in a timely manner, if at all. Patient enrollment is affected by factors including, but not limited to:
|
● |
severity
of the disease under investigation; |
|
|
|
|
● |
design
of the trial protocol; |
|
|
|
|
● |
the
size and nature of the patient population; |
|
|
|
|
● |
eligibility
criteria for the study in question; |
|
|
|
|
● |
lack
of a sufficient number of patients who meet the enrollment criteria for our clinical trials; |
|
|
|
|
● |
delays
in characterizing a patient’s infection to allow us to select a product candidate, which may lead patients to seek to enroll
in other clinical trials or seek alternative treatments; |
|
|
|
|
● |
perceived
risks and benefits of the product candidate under study; |
|
|
|
|
● |
availability
of competing therapies and clinical trials; |
|
|
|
|
● |
efforts
to facilitate timely enrollment in clinical trials; |
|
● |
clinical
trial sites being overtaxed by treating COVID-19 patients; |
|
|
|
|
● |
scheduling
conflicts with participating clinicians; |
|
|
|
|
● |
patient
referral practices of physicians; |
|
|
|
|
● |
the
ability to monitor patients adequately during and after treatment; and |
|
|
|
|
● |
proximity
and availability of clinical trial sites for prospective patients. |
The
COVID-19 pandemic continues to impact on clinical trial enrollment worldwide. We have experienced slower enrollment of patients in our
clinical trials due to the pace in which clinical sites were being initiated for enrollment and may experience similar difficulties in
the future. In addition, AR-301 has been granted orphan drug designation for the treatment of S. aureus in the EU, and the low
prevalence of such diseases relative to the total population may make it harder to identify patients to enroll. If we have difficulty
enrolling a sufficient number or diversity of patients to conduct our clinical trials as planned, we may need to delay or terminate ongoing
or planned clinical trials, either of which would have an adverse effect on our business.
Our
product candidates are based on a novel technology, which may raise development issues we may not be able to resolve, regulatory issues
that could delay or prevent approval, or personnel issues that may keep us from being able to develop our product candidates.
Our
product candidates are based on our mAb technology and gallium-based anti-infective platforms. There can be no assurance that development
problems related to our novel technologies will not arise in the future that will cause significant delays or that we will able to resolve.
Regulatory
approval of novel product candidates such as ours can be more expensive and take longer than for other, more well-known or extensively
studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies’ lack of experience with them.
We believe three mAbs have been approved by the FDA to date, and four other mAbs have received Emergency Use Authorization (for COVID-19
treatment). The approved mAbs are Synagis® which stimulates the immune system to target a viral infection, Anthim® which treats
inhalational anthrax in combination with appropriate antibiotics, and ZINPLAVA® to reduce recurrence of Clostridium difficile
infections. The novelty of our platform may lengthen the regulatory review process, require us to conduct additional studies or clinical
trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization
of our product candidates or lead to significant post-approval limitations or restrictions. For example, the FDA could require additional
studies that may be difficult or impossible to perform.
The
novel nature of our product candidates also means that fewer people are trained in or experienced with product candidates of this type,
which may make it difficult to find, hire and retain capable personnel, particularly for research, development, commercialization and
manufacturing positions. For example, study personnel may administer the wrong version of our product candidates or assign study therapy
to the wrong treatment group, resulting in potential disqualification of subjects from data analysis. These factors could potentially
cause a trial to fail for a reason unrelated to the efficacy of our product candidates. If we are unable to hire and retain the necessary
personnel, the rate and success at which we can develop and commercialize product candidates will be limited. Any such events would increase
our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely impact our business,
financial condition and results of operations.
If
we are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience significant delays
in doing so, we may not realize the full commercial potential of our product candidates.
We
intend to use rapid diagnostic tests of patients’ respiratory samples to target our mAb product candidates to those patients we
believe are infected with the bacterial agents which our mAb will act against. However, currently there is no commercially available
companion diagnostic for AR-101 and AR-401. Therefore, there is a risk that a companion diagnostic for these products are not developed
or available to support product launch. The FDA and similar regulatory authorities outside the United States regulate companion diagnostics.
Companion diagnostics require separate or coordinated regulatory approval prior to commercialization of the therapeutic product. Changes
to applicable regulations could delay our development programs or delay or prevent eventual marketing approval for our product candidates
that may have otherwise been approved.
The
FDA’s evolving position on the topic of companion diagnostics could affect our clinical development programs that utilize companion
diagnostics. In particular, the FDA may limit our ability to use retrospective data, otherwise disagree with our approaches to trial
design, biomarker qualification, clinical and analytical validity, and clinical utility, or make us repeat aspects of a trial or initiate
new trials.
Assays
that can be used as companion diagnostics are commercially available, but in some cases such as for AR-101, they do not yet have regulatory
approval for use as companion diagnostic. We have limited experience in the development of diagnostics and may not be successful in developing
necessary diagnostics to pair with those product candidates that require a companion diagnostic.
Given
our limited experience in developing diagnostics, we expect to rely in part on third parties for their design and manufacture. If we,
or any third parties that we engage to assist us, are unable to successfully develop companion diagnostics for our product candidates
that require such diagnostics, or experience delays in doing so, the development of our product candidates may be adversely affected,
our product candidates may not receive marketing approval and we may not realize the full commercial potential of any products that receive
marketing approval. As a result, our business could be materially harmed.
Clinical
development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and clinical trials may not
be predictive of future trial results.
Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during
the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive
of the design or results of later-stage clinical trials. The results regarding initial tolerability and clinical activity generated to
date in clinical trials for our AR-301 and AR-101 product candidates in HAP and VAP patients do not ensure that later clinical trials
will demonstrate similar results. While we have observed in exploratory analysis statistically significant improvements in the outcomes
of some of our clinical trials, many of the improvements we have seen have not reached statistical significance. Statistical significance
is a statistical term that means that an effect is unlikely to have occurred by chance. In order to be approved by the FDA, European
Medicines Agency, or other drug approving authorities, product candidates must demonstrate that their effect on patients’ diseases
in the trial is statistically significant and clinically meaningful. Product candidates in later stages of clinical trials may fail to
show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Early
clinical trials frequently enroll patient populations that are different from the patient populations in later trials, resulting in different
outcomes in later clinical trials from those in earlier stage clinical trials. In addition, adverse events may not occur in early clinical
trials and only emerge in larger, late-stage clinical trials or after commercialization. Companies in the biopharmaceutical industry
have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising
results in earlier clinical trials. If later stage clinical trials do not demonstrate efficacy and safety of our product candidates,
we will not be able to market them and our business will be materially harmed.
We
may seek a breakthrough therapy designation for our existing and future product candidates, but we might not receive such designation,
and even if we do, such designation may not lead to a faster development or regulatory review or approval process.
We
may seek a breakthrough therapy designation for our existing and future product candidates; however, we cannot assure you our product
candidates will meet the criteria for that designation. A breakthrough therapy is defined as a therapy that is intended, alone or in
combination with one or more other therapies, to treat a serious condition, and preliminary clinical evidence indicates that the therapy
may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. For therapies and biologics that have been designated as breakthrough therapies,
interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies
by the FDA may also be eligible for priority review if supported by clinical data at the time the new drug application is submitted to
the FDA.
Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets
the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even
if we receive breakthrough therapy designation, the receipt of such designation for a product candidate may not result in a faster development
or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure
ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may
later decide that the product candidate no longer meets the conditions for qualification or decide that the time period for FDA review
or approval will not be shortened.
Designation
of our product candidates as qualified infectious disease products is not assured and, in any event, even if granted, may not actually
lead to a faster development or regulatory review, and would not assure FDA approval of our product candidates.
We
may seek designation of our existing and future product candidates as QIDP. A QIDP is an antibacterial or antifungal drug intended to
treat serious or life- threatening infections, including those caused by an antibacterial or antifungal resistant pathogen, including
novel or emerging infectious pathogens or certain “qualifying pathogens.” A product designated as a QIDP for a particular
indication will also be granted priority review by the FDA and can qualify for fast track status. Upon the approval of an NDA for a drug
product designated by the FDA as a QIDP, the product is granted a period of five years of regulatory exclusivity that is in addition
to any other period of regulatory exclusivity for which the product is eligible. The FDA has broad discretion whether or not to grant
these designations, so even if we believe a particular product candidate is eligible for such designation or status, the FDA could decide
not to grant it. Moreover, even if we do receive such a designation, we may not experience a faster development process, review or approval
compared to conventional FDA procedures and there is no assurance that our product candidate, even if determined to be a QIDP, will be
approved by the FDA.
Regulatory
authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials.
The
time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities.
In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate’s clinical development and may vary among jurisdictions. We have discussions with and obtain guidance
from regulatory authorities regarding certain aspects of our clinical development activities. These discussions are not binding commitments
on the part of regulatory authorities. Under certain circumstances, regulatory authorities may revise or retract previous guidance during
the course of our clinical activities or after the completion of our clinical trials. A regulatory authority may also disqualify a clinical
trial in whole or in part from consideration in support of approval of a potential product for commercial sale or otherwise deny approval
of that product. Prior to regulatory approval, a regulatory authority may elect to obtain advice from outside experts regarding scientific
issues and/or marketing applications under a regulatory authority review. In the United States, these outside experts are convened through
the FDA’s Advisory Committee process, which would report to the FDA and make recommendations that may differ from the views of
the FDA. Should an Advisory Committee be convened, it would be expected to lengthen the time for obtaining regulatory approval, if such
approval is obtained at all.
The
FDA and foreign regulatory agencies may delay, limit or deny marketing approval for many reasons, including, but not limited to:
|
● |
a
product candidate may not be considered safe or effective; |
|
|
|
|
● |
our
manufacturing processes or facilities may not meet the applicable requirements; |
|
|
|
|
● |
changes
in the agencies’ approval policies or adoption of new regulations may require additional work on our part, for example, the
FDA may require us to change or expand the endpoints in our clinical trials; |
|
|
|
|
● |
different
divisions of the FDA are reviewing different product candidates and those divisions may have different requirements for approval;
and |
|
|
|
|
● |
changes
in regulatory law, FDA or foreign regulatory agency organization, or personnel may result in different requirements for approval
than anticipated. |
Our
product candidates may not be approved even if they achieve their endpoints in clinical trials. Regulatory agencies, including the FDA,
or their advisors may disagree with our trial design and our interpretations of data from preclinical studies and clinical trials. Regulatory
agencies also may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the
performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable
for the successful commercialization of our product candidates. We have not obtained regulatory approval for any product candidate, and
it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever
obtain regulatory approval.
Any
delay in or failure to receive or maintain approval for any of our product candidates could prevent us from ever generating revenues
or achieving profitability.
We
may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements,
the results are negative or inconclusive, or the trials are not well designed.
Clinical
trials must be conducted in accordance with FDA regulations governing clinical studies, or other applicable foreign government guidelines,
and are subject to oversight by the FDA, other foreign governmental agencies and IRBs/Ethic Committees at the medical institutions where
the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced under current Good
Manufacturing Practices, or cGMP, and may require large numbers of test subjects. Clinical trials may be suspended by the FDA, other
foreign governmental agencies or us for various reasons, including, but not limited to:
|
● |
deficiencies
in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements
or clinical protocols; |
|
|
|
|
● |
deficiencies
in the clinical trial operations or trial sites; |
|
|
|
|
● |
the
product candidate may have unforeseen adverse side effects; |
|
|
|
|
● |
the
time required to determine whether the product candidate is effective may be longer than expected; |
|
|
|
|
● |
deaths
or other adverse events arising during a clinical trial due to medical problems that may not be related to clinical trial treatments; |
|
|
|
|
● |
the
product candidate may not appear to be more effective than current therapies; |
|
|
|
|
● |
the
quality or stability of the product candidate may fall below acceptable standards; and |
|
|
|
|
● |
insufficient
quantities of the product candidate might be available to complete the trials. |
In
addition, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these
changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing
or successful completion of a clinical trial. Due to these and other factors, our product candidates could take longer to gain regulatory
approval than we expect or we may never gain approval for any product candidates, which could reduce or eliminate our revenue by delaying
or terminating the commercialization of our product candidates.
A
Fast Track product designation or other designation to facilitate product candidate development may not lead to faster development or
regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.
We
have received a Fast Track product designation for AR-301 and AR-320 and we may seek Fast Track designation for other of our current
or future product candidates. Receipt of a designation to facilitate product candidate development is within the discretion of the FDA.
Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree. In any event,
the receipt of such a designation for a product candidate may not result in a faster development process, review, or approval compared
to drugs considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition,
the FDA may later decide that the products no longer meet the designation conditions.
We
may not be able to maintain orphan drug marketing exclusivity for our AR-501 and AR-301 product candidates in the United States and/or
the European Union, and orphan drug marketing exclusivity may not be available for any of our other product candidates.
Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition (with
a population of less than 200,000), which is defined as one occurring in a patient population of fewer than 200,000 in the United States,
or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of developing the drug
or biologic will be recovered from sales in the United States. In the EU, following the opinion of the EMA’s Committee for Orphan
Medicinal Products, the European Commission grants orphan drug designation to a product if (1) it is intended for the diagnosis, prevention
or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in
10,000 persons in the EU when the application is made, or (b) the product, without the incentives derived from orphan medicinal product
status, would not generate sufficient return in the EU to justify investment; and (3) there exists no satisfactory method of diagnosis,
prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant
benefit to those affected by the condition.
Generally,
if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such
designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the European Commission and the competent
authorities in the EU Member States from approving another marketing application for the same drug (or similar medicinal product in the
European Union) for that time period, except in limited circumstances. The applicable period is seven years in the U.S. and 10 years
in the EU. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or
if the drug is sufficiently profitable that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA
determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of
the drug to meet the needs of patients with the rare disease or condition.
We
have been granted orphan drug designation for our AR-501 and AR-301 drug candidates in the European Union, as well as orphan drug designation
for our AR-501 drug candidate in the U.S. Although we may apply for orphan drug designation for other product candidates, we may develop
in both the U.S. and EU, applicable regulatory authorities may not grant us this designation. In addition, even if such status is obtained
for any other product candidate that we may develop, that exclusivity may not effectively protect the candidate from competition because
other drugs, such as those with different active ingredients or molecular structures, can be approved for the same condition. Furthermore,
even after an orphan drug is approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that
the later drug is clinically superior, in that it is shown to be safer, more effective or makes a major contribution to patient care.
In the EU, a marketing authorization may be granted to a similar product during the 10-year period of market exclusivity for the same
therapeutic indication at any time if:
|
● |
the
second applicant can establish in its application that its product, although similar to the orphan medicinal product already authorized,
is safer, more effective or otherwise clinically superior; |
|
|
|
|
● |
the
holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application;
or |
|
|
|
|
● |
the
holder of the marketing authorization for the original orphan medicinal product cannot supply enough orphan medicinal product. |
Any
inability to secure orphan drug designation or to maintain the exclusivity benefits of this designation could have an adverse impact
on our ability to develop and commercialize our product candidates, depending on the extent to which we would be protected by other patents
and regulatory exclusivities, and may adversely affect our business, prospects, financial condition and results of operations.
Any
product candidate for which we, or our collaborators, obtain marketing approval could be subject to restrictions or withdrawal from the
market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems
with our products, when and if any of them are approved.
Any
product candidate that we, or our collaborators, obtain marketing approval for, along with the manufacturing processes, post-approval
clinical data, labeling, advertising and promotional activities for such product, will be subject to continuing requirements of the FDA
and other regulatory authorities. These requirements include submissions of safety and other post-marketing information, reports, facility
registration and product listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance
of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval
of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed
or to conditions of approval or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy
of the product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the
approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’
communications regarding off-label use. If we market our products outside of their approved indications, we will be subject to enforcement
action for off-label marketing.
In
addition, later discovery of previously unknown problems with these products, manufacturers or manufacturing processes, or failure to
comply with regulatory requirements, may yield various results, including, but not limited to:
|
● |
restrictions
on such products, manufacturers or manufacturing processes; |
|
|
|
|
● |
restrictions
on the labeling or marketing of a product; |
|
|
|
|
● |
restrictions
on product distribution or use; |
|
|
|
|
● |
requirements
to conduct post-marketing clinical trials; |
|
|
|
|
● |
warning
or untitled letters; |
|
|
|
|
● |
withdrawal
of the products from the market; |
|
|
|
|
● |
refusal
to approve pending applications or supplements to approved applications that we submit; |
|
|
|
|
● |
recall
of products, fines, restitution or disgorgement of profits or revenue; |
|
|
|
|
● |
suspension
or withdrawal of marketing approvals; |
|
|
|
|
● |
refusal
to permit the import or export of our products; |
|
|
|
|
● |
product
seizure; and |
|
|
|
|
● |
injunctions
or the imposition of civil or criminal penalties. |
The
FDA’s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. If we, or our collaborators, are slow or unable to adapt to changes in existing requirements or the adoption
of new requirements or policies, or if we, or our collaborators, are not able to maintain regulatory compliance, any marketing approval
that was obtained could be lost, which would adversely affect our business, prospects and ability to achieve or sustain profitability.
If
we, or our collaborators, are unable to comply with foreign regulatory requirements or obtain foreign regulatory approvals, our ability
to develop foreign markets for our products could be impaired.
Sales
of our products outside the U.S. will be subject to foreign regulatory requirements governing clinical trials, marketing approval, manufacturing,
product licensing, pricing and reimbursement. These regulatory requirements vary greatly from country to country. As a result, the time
required to obtain approvals outside the U.S. may differ from that required to obtain FDA approval and we may not be able to obtain foreign
regulatory approvals on a timely basis or at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries,
and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA
and foreign regulatory authorities could require additional testing. Failure to comply with these regulatory requirements or obtain required
approvals could impair our ability to develop foreign markets for our products.
We
are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering
laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets.
We can face criminal liability and other serious consequences for violations, which can harm our business.
We
are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations,
various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls,
the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. §
201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries
in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors,
and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else
of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States,
to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations,
and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated
hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees,
agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any
violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment,
the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and
other consequences.
Our
business may be adversely impacted by the consequences of Russia’s invasion of Ukraine.
Economic,
political and social conditions resulting from Russia’s invasion of Ukraine could materially disrupt our clinical trials, increase
our costs and may disrupt planned clinical development activities. For example, our AR-320 clinical trial currently has planned clinical
sites in Russia, Ukraine and Belarus. To the extent the conflict between Ukraine and Russia adversely impacts our ability to enroll patients
or complete enrollments in process or adversely impacts the ability of our suppliers to produce and distribute the supplies we need for
our AR-320 clinical trial, the timing for completing our AR-320 trial may be adversely impacted. In addition, the United States, United
Kingdom and European Union governments, among others, have instituted various sanctions and export-control measures in response to the
invasion, including comprehensive financial sanctions, targeted at Russia or designated individuals and entities with business interests
and/or government connections to Russia or those involved in Russian military activities. Governments have also enhanced export controls
and trade sanctions targeting Russia’s imports of goods. The duration and intensity of this conflict and its economic impact on
our European operations is uncertain at this time, but it is possible that our business, results of operations and financial condition
could be materially and adversely affected.
Developing
product candidates in combination with other therapies may lead to unforeseen side effects or failures in our clinical trials.
We,
and our collaborators, are studying our product candidates in clinical trials in combination with approved therapies, including antibiotics,
and we anticipate that if any product candidates are approved for marketing, they will be approved to be used only in combination with
other therapies. Our development programs and planned studies carry all the risks inherent in drug development activities, including
the risk that they will fail to demonstrate meaningful efficacy or acceptable safety. In addition, our development programs are subject
to additional regulatory, commercial, manufacturing and other risks because of the use of other therapies in combination with our product
candidates. For example, the other therapies may lead to toxicities that are improperly attributed to our product candidates or the combination
of our product candidates with other therapies may result in toxicities that the product candidate or other therapy does not produce
when used alone. The other therapies we are using in combination with our product candidates may be removed from the market or become
prohibitively expensive and thus be unavailable for testing or commercial use with any of our approved products. Testing product candidates
in combination with other therapies may increase the risk of significant adverse effects or test failures. The timing, outcome and cost
of developing products to be used in combination with other therapies is difficult to predict and dependent on a number of factors that
are outside our reasonable control. If any safety or toxicity issues arise in these clinical trials or with any approved products, or
if the other therapies are removed from the market, the products may not be approved, which could prevent us from ever generating revenues
or achieving profitability.
We
will need to develop or acquire additional manufacturing and distribution capabilities, or outsource the same to third parties, in order
to commercialize any product candidates that obtain marketing approval, and we may encounter unexpected costs or difficulties in doing
so.
If
we independently develop and commercialize one or more of our product candidates, we will need to invest in acquiring or building additional
capabilities and effectively manage our operations and facilities to successfully pursue and complete future research, development and
commercialization efforts. We will require additional investment and validation process development in order to qualify our commercial-scale
manufacturing process to manufacture clinical trial materials and commercial material if any of our products are approved for marketing.
This investment and validation process development may be expensive and time-consuming. We will require additional personnel with experience
in commercial-scale manufacturing, managing of large-scale information technology systems and managing a large-scale distribution system.
We will need to add personnel and expand our capabilities, which may strain our existing managerial, operational, regulatory compliance,
financial and other resources. To do this effectively, we must:
|
● |
recruit,
hire, train, manage and motivate a growing employee base; |
|
|
|
|
● |
accurately
forecast demand for our products; |
|
|
|
|
● |
assemble
and manage the supply chain to ensure our ability to meet demand; and |
|
|
|
|
● |
expand
existing operational, manufacturing, financial and management information systems. |
We
may seek FDA approval for our production process and facilities simultaneously with seeking approval for sale of our product candidates.
Should we not complete the development of adequate manufacturing and distribution capabilities, including manufacturing capacity, or
fail to receive timely approval of our manufacturing process and facilities, our ability to supply clinical trial materials for planned
clinical trials or supply products following regulatory approval for sale could be delayed, which would further delay our clinical trials
or the period of time when we would be able to generate revenues from the sale of such products, if we are even able to obtain approval
or generate revenues at all.
Additionally,
we may decide to outsource some or all of our manufacturing activities to a third-party commercial manufacturing organization, or CMO.
Under any agreement with a CMO, we would have less control over the timing and quality of manufacturing than if we were to perform such
manufacturing ourselves. A CMO would be manufacturing other pharmaceutical products in the same facilities as our product candidates,
increasing the risk of cross product contamination. Further, there is no guarantee that any CMO will continue ongoing operations, causing
potential delays in product supply, reduced revenues and other liabilities for us.
Any
such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely
impact our business, financial condition and results of operations.
Our
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
Undesirable
side effects caused by our product candidates could cause us, our collaborators, or regulatory authorities to interrupt, delay or halt
clinical trials and could result in a more restrictive label, the delay or denial of regulatory approval by the FDA or other comparable
foreign regulatory authorities, or litigation by injured patients, if any. To date, patients treated with AR-301, AR-501 and AR-101 have
experienced AEs related to the study drug, some of which have been serious. Regarding AR-301, few (2.2%) adverse events, or AEs, were
deemed related, and no serious adverse events, or SAEs, were deemed to be related to AR-301 treatment. There were 31 deaths in the trial,
none of which were deemed related to AR-301. Regarding AR-501, there have been a total of 12 AEs reported of which six were related to
AR-501 in the ongoing Phase 2a clinical trial. To date, there have been no SAEs and no deaths in this trial. Regarding AR-101, 12 SAEs
were experienced by five subjects. An event of cardiorespiratory arrest was judged as probably related to AR-101 and events of hyperbilirubinemia
and cholestasis, although pre-existent, were deemed possibly related. In both cases, the causality assessment by the investigators accounted
for the fact that a contribution by AR-101 to the AE could not be excluded with certainty although other probable causes were acknowledged.
The other SAEs were deemed unrelated. The AR-701 mAbs may exhibit a reduction or complete loss of efficacy due to the emergence of new
SARS-CoV-2 mutant virus variants.
Because
our product candidates are intended to assist the immune system, our clinical trials could reveal an unacceptable severity and prevalence
of side effects, including, but not limited to, adverse immune responses that lead to previously unobserved complications. As a result
of any side effects, our clinical trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could
order us to cease further development, or deny approval, of our product candidates for any or all targeted indications. The drug-related
side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product
liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.
Additionally,
if one or more of our product candidates receives marketing approval, and we, our collaborators, or others later identify undesirable
side effects caused by such products, a number of potentially significant negative consequences could result, including, but not limited
to:
|
● |
regulatory
authorities may withdraw approvals of such product; |
|
|
|
|
● |
regulatory
authorities may require additional warnings on the label; |
|
|
|
|
● |
we
may be required to create a medication guide outlining the risks of such side effects for distribution to patients; |
|
|
|
|
● |
we
may be sued and held liable for harm caused to patients; and |
|
|
|
|
● |
our
reputation may suffer. |
In
addition, we cannot assure you that the bacteria which our mAbs target will not in the future develop a resistance to our mAbs.
Any
of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and
could significantly harm our business, results of operations and prospects.
If
we cannot conduct the non-clinical testing required by regulatory authorities to demonstrate an acceptable toxicity profile for our product
candidates in non-clinical studies, we will not be able to initiate or continue clinical trials or obtain approval for our product candidates.
In
order to move a product candidate into human clinical trials, we must first demonstrate an acceptable toxicity profile in preclinical
testing. Furthermore, in order to obtain approval, we must also demonstrate safety in various non-clinical tests. We may not have conducted
or may not conduct the types of non-clinical testing required by regulatory authorities, or future non-clinical tests may indicate that
our product candidates are not safe for use. Preclinical and non-clinical testing is expensive, time-consuming and has an uncertain outcome.
In addition, success in initial non-clinical testing does not ensure that later non-clinical testing will be successful. We may experience
numerous unforeseen events during, or as a result of, the non-clinical testing process, which could delay or prevent our ability to develop
or commercialize our product candidates, including, but not limited to:
|
● |
our
preclinical and non-clinical testing may produce inconclusive or negative safety results, which may require us to conduct additional
non-clinical testing or to abandon product candidates; |
|
|
|
|
● |
our
product candidates may have unfavorable pharmacology or toxicity characteristics; |
|
|
|
|
● |
our
product candidates may cause undesirable side effects such as negative immune responses that lead to complications; |
|
|
|
|
● |
our
enrolled patients may have allergies that lead to complications after treatment; and |
|
|
|
|
● |
the
FDA or other regulatory authorities may determine that additional safety testing is required. |
Any
such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which could adversely
impact our business, financial condition and results of operations.
Because
we have multiple product candidates in our clinical pipeline and are considering a variety of target indications, we may expend our limited
resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may
be more profitable or for which there is a greater likelihood of success.
Because
we have limited financial and managerial resources, we must focus our research and development efforts on those product candidates and
specific indications that we believe are the most promising. As a result, we may forego or delay our pursuit of opportunities with other
product candidates or other indications that later prove to have greater commercial potential. Our resource allocation decisions may
cause us to fail to capitalize on viable commercial products or profitable market opportunities. We may in the future spend our resources
on other research programs and product candidates for specific indications that ultimately do not yield any commercially viable products.
Furthermore, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish
valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have
been more advantageous for us to retain sole development and commercialization rights.
If
we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product
candidates, we may not be successful in commercializing our product candidates if and when they are approved.
We
do not have a sales and marketing infrastructure or any experience in the sales, marketing or distribution of pharmaceutical products.
We may seek additional third-party collaborators for the commercialization of our other product candidates. In the future, we may choose
to build a focused sales and marketing infrastructure to market or co-promote some of our product candidates if and when they are approved,
which would be expensive and time-consuming. Alternatively, we may elect to outsource these functions to third parties. Either approach
carries significant risks. For example, recruiting and training a sales force is expensive and time-consuming and, if done improperly,
could delay a product launch and result in limited sales. If the commercial launch of a product candidate for which we recruit a sales
force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred
these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and
marketing personnel. Outsourcing sales and marketing capabilities will depend on our ability to enter into and maintain agreements with
other companies having sales, marketing and distribution capabilities, the ability of such companies to successfully market and sell
our product candidates, and our ability to enter into such agreements on terms favorable to us.
Factors
that may inhibit our efforts to commercialize our products on our own include, but are not limited to:
|
● |
our
inability to recruit, manage and retain adequate numbers of effective sales and marketing personnel; |
|
● |
the
inability of marketing personnel to develop effective marketing materials; |
|
● |
the
inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products; |
|
● |
the
lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies
with more extensive product lines; and |
|
● |
unforeseen
costs and expenses associated with creating an independent sales and marketing organization. |
Entry
into agreements with third parties to sell and market our product candidates will subject us to a number of risks, including, but not
limited to, the following:
|
● |
we
may be required to relinquish important rights to our products or product candidates; |
|
● |
we
may not be able to control the amount and timing of resources that our distributors or collaborators may devote to the commercialization
of our product candidates; |
|
● |
distributors
or collaborators may experience financial difficulties; |
|
● |
our
distributors or collaborators may not devote sufficient time to the marketing and sales of our products; and |
|
● |
business
combinations or significant changes in a collaborator’s business strategy may adversely affect a collaborator’s willingness
or ability to complete its obligations under any arrangement. |
The
availability and amount of reimbursement for our product candidates, if approved, and the manner in which government and private payors
may reimburse for any potential products, are uncertain.
Obtaining
coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor.
There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited
than the purposes for which the product is approved by the FDA or similar regulatory authorities outside of the United States. Moreover,
eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs,
including research, development, intellectual property, manufacture, sale and distribution expenses. Reimbursement rates may vary according
to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost
products and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts
or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict
imports of product from countries where they may be sold at lower prices than in the United States.
There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Third-party payors often rely
upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and
approval process apart from Medicare coverage and reimbursement determinations. It is difficult to predict at this time what third-party
payors will decide with respect to the coverage and reimbursement for our product candidates. Our inability to promptly obtain coverage
and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial
condition.
Reimbursement
may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a
given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients
find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians,
generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to
use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products.
Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and
economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available
or subsequently become available.
The
U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment
programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage
and requirements for substitution of generic products for branded prescription drugs. Adoption of government controls and measures and
tightening of restrictive policies in jurisdictions with existing controls and measures, could exclude or limit our products from coverage
and limit payments for pharmaceuticals.
In
addition, we expect that the increased emphasis on managed care and cost containment measures in the U.S. by third-party payors and government
authorities to continue and will place pressure on pharmaceutical pricing and coverage. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more drug products for which
we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
Failure
to attract and retain key personnel could impede our ability to develop our products and to obtain new collaborations or other sources
of funding.
Because
of the specialized scientific nature of our business and the novel properties of our antibody platform, our success is highly dependent
upon our ability to attract and retain qualified scientific and technical personnel, consultants and advisors. We depend greatly on our
founders Dr. Vu Truong, our Chief Executive Officer, Chief Scientific Officer and a Director, and Dr. Eric Patzer, our Executive Chairman.
We will also need to recruit a significant number of additional personnel in order to achieve our operating goals and financial reporting
obligations. In order to pursue our product development and marketing and sales plans, we will need to hire additional qualified scientific
personnel to perform research and development, as well as personnel with expertise in clinical testing, government regulation, manufacturing,
marketing and sales, which may strain our existing managerial, operational, regulatory compliance, financial and other resources. We
also rely on consultants and advisors to assist in formulating our research and development strategy and adhering to complex regulatory
requirements. We face competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities and
other research institutions. There can be no assurance that we will be able to attract and retain such individuals on acceptable terms,
if at all. The failure to attract and retain qualified personnel, consultants and advisors could have a material adverse effect on our
business, financial condition and results of operations.
We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success.
Because
we have limited financial and managerial resources, we focus on research programs and product candidates for the indications that we
believe are the most scientifically and commercially promising. Our resource allocation decisions may cause us to fail to capitalize
on viable scientific or commercial products or profitable market opportunities. In addition, we may spend valuable time and managerial
and financial resources on research programs and product candidates for specific indications that ultimately do not yield any scientifically
or commercially viable products. If we do not accurately evaluate the scientific and commercial potential or target market for a particular
product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements
in situations where it would have been more advantageous for us to retain sole rights to development and commercialization.
Risks
Relating to Manufacturing Activities
We
have no experience manufacturing our product candidates at commercial scale, and there can be no assurance that our product candidates
can be manufactured in compliance with regulations at a cost or in quantities necessary to make them commercially viable. There can be
no assurance that any contract manufacturing facilities will be acceptable for licensure by regulatory authorities or that we can contract
to build acceptable facilities.
We
have no experience in commercial-scale manufacturing of mAbs. We may develop our manufacturing capacity in part by building manufacturing
facilities. This activity would require substantial additional funds and we would need to hire and train significant numbers of qualified
employees to staff these facilities. We may not be able to develop commercial-scale manufacturing facilities that are adequate to produce
materials for additional later-stage clinical trials or commercial use. We currently rely on CMOs for bulk product manufacturing and
sterile fill and finish of our products, and these contractors currently manufacture our product candidates at a scale that is not adequate
for commercial supply. Failure to find and maintain satisfactory commercial-scale manufacturing contractors could impair our ability
to supply product for clinical and commercial needs. Additionally, we may decide to outsource some or all of our bulk product manufacturing
activities to a third-party CMO. Failure of any of these contractors to maintain compliance with cGMPs and other regulatory and legal
requirements could result in government actions that would limit or eliminate clinical trial and commercial product supply. Under any
agreement with a CMO, we would have less control over the timing and quality of manufacturing than if we were performing such manufacturing
ourselves. A CMO would be manufacturing other pharmaceutical products in the same facilities as our product candidates, increasing the
risk of cross product contamination. Further, there is no guarantee that any CMO will continue ongoing operations, causing potential
delays in product supply, reduced revenues and other liabilities for us.
The
equipment and facilities employed in the manufacture of pharmaceuticals are subject to stringent qualification requirements by regulatory
agencies, including validation of equipment, systems and processes. We may be subject to lengthy delays and expense in conducting validation
studies, if we can meet the requirements at all.
If
we are unable to manufacture or contract for a sufficient supply of our product candidates on acceptable terms, or if we encounter delays
or difficulties in our manufacturing processes or our relationships with other manufacturers, our preclinical and clinical testing schedule
would be delayed. This in turn would delay the submission of product candidates for regulatory approval and thereby delay the market
introduction and subsequent sales of any products that receive regulatory approval, which would have a material adverse effect on our
business, financial condition and results of operations. Furthermore, we or our contract manufacturers must supply all necessary documentation
in support of our regulatory approval applications on a timely basis and must adhere to cGMP regulations enforced by the FDA and other
regulatory bodies through their facilities inspection programs. If these facilities cannot pass a pre-approval plant inspection, the
approval by the FDA or other regulatory bodies of the products will not be granted. If the FDA or a comparable foreign regulatory authority
does not approve our facilities and processes for the manufacture of our product candidates or if they withdraw any such approval in
the future, we may need to correct the issues or find alternative manufacturing facilities, which would significantly impact our ability
to develop, obtain regulatory approval for or market our product candidates, if approved.
Our
contract manufacturers are subject to significant regulation with respect to manufacturing of our products.
All
entities involved in the preparation of a product candidate for clinical trials or commercial sale, including our contract manufacturing
organizations used for bulk product manufacturing and filling and finishing of our bulk product, are subject to extensive regulation.
Components of a finished product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance
with cGMP. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation
of quality systems to control and assure the quality of investigational products and products approved for sale. The facilities and quality
systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations
as a condition of any regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit
or inspect a manufacturing facility involved with the preparation of our product candidates or the associated quality systems for compliance
with the regulations applicable to the activities being conducted. The regulatory authorities also may, at any time following approval
of a product for sale, audit the manufacturing facilities of our third-party contractors or raw material suppliers. If any such inspection
or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations
occurs independent of such an inspection or audit, the relevant regulatory authority may require remedial measures that may be costly
and time-consuming to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or
the temporary or permanent closure of a facility. Our third-party contractors or raw material suppliers may refuse to implement remedial
measures required by regulatory authorities. Any failure to comply with applicable manufacturing regulations or failure to implement
required remedial measures imposed upon third parties with whom we contract could materially harm our business.
We
rely on relationships with third-party contract manufacturers and raw material suppliers, which limits our ability to control the availability
of, and manufacturing costs for, our product candidates.
Problems
with any of our contract manufacturers’ or raw material suppliers’ facilities or processes, could prevent or delay the production
of adequate supplies of finished products. This could delay clinical trials or delay and reduce commercial sales and materially harm
our business. Any prolonged delay or interruption in the operations of our collaborators’ facilities or contract manufacturers’
facilities could result in cancellation of shipments, loss of components in the process of being manufactured or a shortfall in availability
of a product candidate or products. A number of factors could cause interruptions, including, but not limited to:
|
● |
the
inability of a supplier to provide raw materials; |
|
● |
equipment
malfunctions or failures at the facilities of our collaborators or suppliers; |
|
● |
employee
absenteeism as a result of coronavirus outbreaks; |
|
● |
high
process failure rates; |
|
● |
damage
to facilities due to natural or man-made disasters; |
|
● |
changes
in regulatory requirements or standards that require modifications to our or our collaborators’ and suppliers’ manufacturing
processes; |
|
● |
action
by regulatory authorities or by us that results in the halting or slowdown of production of components or finished product at our
facilities or the facilities of our collaborators or suppliers; |
|
● |
problems
that delay or prevent manufacturing technology transfer to another facility, contract manufacturer or collaborator with subsequent
delay or inability to start up a commercial facility; |
|
● |
a
contract manufacturer or supplier going out of business, undergoing a capacity shortfall or otherwise failing to produce product
as contractually required; |
|
● |
employee
or contractor misconduct or negligence; and |
|
● |
shipping
delays, losses or interruptions; and other similar factors. |
Because
manufacturing processes are complex and are subject to a lengthy regulatory approval process, alternative qualified production capacity
and sufficiently trained or qualified personnel may not be available on a timely or cost-effective basis or at all. Difficulties or delays
in our contract manufacturers’ production of drug substances could delay our clinical trials, increase our costs, damage our reputation,
and cause us to lose revenue and market share if we are unable to timely meet market demand for any products that are approved for sale.
The
manufacturing process for our product candidates has several components that are sourced from a single manufacturer. If we utilize an
alternative manufacturer or alternative component, we may be required to demonstrate comparability of the drug product before releasing
the product for clinical use and we may not be to find an alternative supplier. For example, the stoppers used to seal the vials of our
products are made by a single supplier using a proprietary formula and process. Any change to the stopper would require us to carry out
lengthy studies to verify that our product remains stable with the replacement stopper. The loss of any of our current suppliers could
result in manufacturing delays for the component substitution, and we may need to accept changes in terms or price from our existing
supplier in order to avoid such delays.
Further,
if our contract manufacturers are not in compliance with regulatory requirements at any stage, including post-marketing approval, we
may be fined, forced to remove a product from the market and/or experience other adverse consequences, including delays, which could
materially harm our business.
A
pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and operations.
The
outbreak of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States
and several European countries. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic
is affecting the United States and global economies and has affected our operations and those of third parties on which we rely, including
by causing disruptions in the supply of our product candidates and the conduct of current and future clinical trials. In addition, the
COVID-19 pandemic has affected the operations of the FDA and other health authorities, which has resulted in delays of reviews and approvals,
including with respect to our product candidates. The evolving COVID-19 pandemic has impacted the pace of enrollment in our Phase 3 pivotal
trial for AR-301 and our Phase 1/2a clinical trial for AR-501 during 2021 and could possibly extend longer as patients may avoid or may
not be able to travel to healthcare facilities and physicians’ offices unless due to a health emergency. Such facilities and offices
may also be required to focus limited resources on non-clinical trial matters, including treatment of COVID-19 patients, and may not
be available, in whole or in part, for clinical trial services related to AR-301 and AR-501 or our other product candidates. Additionally,
while the potential economic impact brought by, and the duration of the COVID-19 pandemic is difficult to assess or predict, the impact
of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our
short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not
yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems
or the global economy as a whole. However, these effects could have a material impact on our liquidity, capital resources, operations
and business and those of the third parties on which we rely.
Business
disruptions could seriously harm future revenue and financial condition and increase our costs and expenses.
Our
operations, and those of our third-party manufacturers, CROs and other contractors and consultants, could be subject to earthquakes,
power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical
epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence
of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.
Our
corporate headquarters are located in Los Gatos, California, an area prone to wildfires and earthquakes. These and other natural disasters
could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition
and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion
of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers,
or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial
period of time. Any disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster
or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity
plans, which, could have a material adverse effect on our business.
Any
disruption in production or inability to produce or ship adequate quantities to meet our needs, whether as a result of a natural disaster
or other causes (such as the recent outbreak of the coronavirus), could impair our ability to operate our business on a day-to-day basis
and to continue our research and development of our product candidates. In addition, we are exposed to the possibility of product supply
disruption and increased costs in the event of changes in the policies of the United States government, political unrest or unstable
economic conditions. Any recall of the manufacturing lots or similar action regarding our API used in clinical trials could delay the
trials or detract from the integrity of the trial data and its potential use in future regulatory filings. In addition, manufacturing
interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development
of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures
could also impede commercialization of our product candidate and impair our competitive position.
We
use and generate hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.
Our
research, development and manufacturing involve the controlled use of hazardous materials, chemicals, various active microorganisms and
volatile organic compounds, and we may incur significant costs as a result of the need to comply with numerous laws and regulations.
For example, as a pharmacologically active material, any residual impurities in process-waste streams must be disposed of as hazardous
waste. We are subject to laws and regulations enforced by the FDA, the Drug Enforcement Agency, foreign health authorities and other
regulatory requirements, including the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation
and Recovery Act, and other current and potential federal, state, local and foreign laws and regulations governing the use, manufacture,
storage, handling and disposal of our products, materials used to develop and manufacture our product candidates, and resulting waste
products. Although we believe that our safety procedures for handling and disposing of such materials, and for killing any unused microorganisms
before disposing of them, comply with the standards prescribed by state and federal regulations, the risk of accidental contamination
or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages
that result and any such liability could exceed our resources.
During
the course of the product life cycle we will make process changes to scale up manufacturing to commercial manufacture or transfer the
production to alternate sites or contract manufacturers. Our ability to successfully implement these changes will depend on our ability
to demonstrate, to the satisfaction of the FDA and other regulatory agencies that the product made by the new process or at the new site
is comparable to the original product.
In
the event that manufacturing process changes are necessary for the further development of a product candidate, we may not be able to
reach agreement with regulatory agencies on the criteria for demonstrating comparability to the original product, which would require
us to repeat clinical studies performed with the original product. This could result in lengthy delays in implementing the new process
or site and consequent delays in regulatory approval and commercial sales of product derived from the new process. If we reach agreement
with regulatory agencies on the criteria for establishing comparability, we may not be able to meet these criteria or may suffer lengthy
delays in meeting these criteria. This may result in significant lost sales due to inability to meet commercial demand with the original
product. Furthermore, studies to demonstrate comparability, or any other studies on the new process or site such as validation studies,
may uncover findings that result in regulatory agencies delaying or refusing to approve the new process or site.
Risks
Relating to Our Joint Venture Agreement
If
our joint venture with Hepalink is not successful or if we fail to realize the benefits we anticipate from such joint venture, we may
not be able to capitalize on the full market potential of our products in China, Hong Kong, Macau and Taiwan.
We
entered into a Joint Venture Contract, as amended effective August 6, 2018, or the JV Agreement, with Shenzhen Hepalink Pharmaceutical
Group Co., Ltd., a People’s Republic of China company, or Hepalink, a related party and significant shareholder in the Company,
pursuant to which we formed a Joint Venture company named Shenzhen Arimab BioPharmaceuticals Co., Ltd., or SABC, a People’s Republic
of China company, develop, manufacture, import and distribute AR-101, AR-301 and AR-105 in China, Hong Kong, Macau and Taiwan, collectively,
referred to as the Territory. The Joint Venture received regulatory approval in China and SABC was formed on July 2, 2018.
Hepalink
contributed the equivalent of $7.2 million in renminbi, the official currency of the People’s Republic of China, and owns 51% of
the capital of SABC and we contributed (i) $1.0 million in cash and (ii) a license to AR-101, AR-301 and AR-105 pursuant to an Amended
and Restated Technology License and Collaboration Agreement between us and SABC and we own 49% of the capital of SABC. It was agreed
by the parties that we shall be reimbursed for certain legal and contract manufacturing expenses related to the clinical drug supply
for a Phase 3 clinical study of AR-301 and the clinical drug supply for a clinical study of AR-105. In addition, Hepalink will provide
SABC with clinical and regulatory personnel services for clinical and regulatory review, application and filing procedures in the Territory
and we will provide clinical and regulatory personnel services to assist in coordination of the execution of the clinical study in China
and also with CMC personnel services for drug supply and manufacturing planning. Hepalink is obligated to make an additional equity investment
of $10.8 million into SABC in connection with a future financing of SABC provided that (i) such financing does not occur earlier than
January 1, 2019, (ii) top-line clinical results of the first global AR-301 Phase 3 study are available, (iii) CFDA approval for a Phase
3 clinical trial in China is granted, (iv) we have not breached the Amended and Restated Technology License and Collaboration Agreement
and (v) the SABC Board has approved such financing. If and to the extent these milestone events occur and Hepalink contributes additional
capital to SABC, our 49% ownership stake in SABC will be diminished in proportion to such investment.
While
SABC is obligated to use its commercial best efforts to commercialize our products and product candidates in the Territory, we have limited
contractual rights to direct its activities. Hepalink has the majority of the voting equity in SABC and has the right to designate three
of five board seats. Therefore, Hepalink may have a greater influence in the commercialization efforts and other operations of SABC.
In general, our joint venture with Hepalink subjects us to a number of related risks including that:
|
● |
SABC
may not commit sufficient resources to the marketing and distribution of our products in the Territory; |
|
● |
SABC
may infringe the intellectual property rights of third parties, which may expose us to litigation and other potential liability; |
|
● |
as
long as we remain a shareholder of SABC, any cash that we contribute to SABC may not be transferred back to us or converted into
USD and thus, may only be used for goods and services in China; |
|
● |
disputes
may arise among SABC, Hepalink and us that result in the delay or termination of the commercialization of our products or product
candidates or that result in costly litigation or arbitration that diverts management attention and resources; and; |
|
● |
SABC
may not provide us with timely and accurate information regarding commercialization status or results, which could adversely impact
our ability to manage our own commercialization efforts, accurately forecast financial results or provide timely information to our
shareholders regarding our commercialization efforts in the Territory. |
While
we believe that our board representation, voting rights and other contractual rights with respect to SABC serve to mitigate some of these
risks, we may have disagreements with the other directors and Hepalink that could impair our ability to influence SABC to act in a manner
that we believe is in the best interests of our Company. Upon the completion of certain milestone events, Hepalink will become obligated
to acquire additional shares of SABC, the proceeds of which would be received by SABC in exchange for newly issued shares. We may not
be able to access the funds for our own operations.
The
laws of the People’s Republic of China, which govern SABC’s management and operations, may not offer the same protections
afforded to minority stockholders under the Delaware General Corporation Law. Consequently, SABC may make business decisions that are
not in our best interests as minority equity holders.
Risks
Relating to Competitive Factors
We
compete in an industry characterized by extensive research and development efforts and rapid technological progress. New discoveries
or commercial developments by our competitors could render our potential products obsolete or non-competitive.
New
developments occur and are expected to continue to occur at a rapid pace in our industry, and there can be no assurance that discoveries
or commercial developments by our competitors will not render some or all of our potential products obsolete or non-competitive, which
could have a material adverse effect on our business, financial condition and results of operations. New data from commercial and clinical-stage
products continue to emerge and it is possible that these data may alter current standards of care, completely precluding us from further
developing our product candidates or preventing us from getting them approved by regulatory agencies. Further, it is possible that we
may initiate a clinical trial or trials for our product candidates, only to find that data from competing products make it impossible
for us to complete enrollment in these trials, resulting in our inability to file for marketing approval with regulatory agencies. Even
if these products are approved for marketing in a particular indication or indications, they may have limited sales due to particularly
intense competition in these markets.
We
expect to compete with fully integrated and well-established pharmaceutical and biotechnology companies in the near- and long-term. Most
of these companies have substantially greater financial, research and development, manufacturing and marketing experience and resources
than we do and represent substantial long-term competition for us. Such companies may succeed in discovering and developing pharmaceutical
products more rapidly than we do or pharmaceutical products that are safer, more effective or less costly than any that we may develop.
Such companies also may be more successful than we are in manufacturing, sales and marketing. Smaller companies may also prove to be
significant competitors, particularly through collaborative arrangements with large pharmaceutical and established biotechnology companies.
Academic institutions, governmental agencies and other public and private research organizations also conduct clinical trials, seek patent
protection and establish collaborative arrangements for the development of product candidates.
We
expect competition among products will be based on product efficacy and safety, the timing and scope of regulatory approvals, availability
of supply, marketing and sales capabilities, reimbursement coverage, price and patent position. There can be no assurance that our competitors
will not develop safer and more effective products, commercialize products earlier than we do, or obtain patent protection or intellectual
property rights that limit our ability to commercialize our products.
There
can be no assurance that our issued patents or pending patent applications, if issued, will not be challenged, invalidated or circumvented
or that the rights granted thereunder will provide us with proprietary protection or a competitive advantage.
Our
competitors may develop and market products that are less expensive, more effective, safer or reach the market sooner than our product
candidates, which may diminish or eliminate the commercial success of any products we may commercialize.
The
biopharmaceutical industry is highly competitive. There are many public and private biopharmaceutical companies, public and private universities
and research organizations actively engaged in the discovery and research and development of products for infectious disease. Several
companies are developing mAbs to treat infections, including Merck & Co., AstraZeneca, VIR Biotechnology, Regeneron, Eli Lilly, Adimab,
Alopexx Enterprises, LLC, etc.
There
is no assurance, however, that another company will not discover how to successfully develop these antibodies for competing indications.
Among
current antimicrobial therapies, antibiotics, particularly those administered by inhalation, can be competitors to our products especially
AR-501 for lung infections. Examples include TOBI (inhaled tobramycin) and Cayston (inhaled aztreonam). Additionally, the introduction
of Vertex’s channel corrector therapies could alter cystic fibrosis patients’ dependencies on chronic antimicrobial therapies.
There are antibiotics being developed for gram-positive or gram-negative bacterial infections that could impact the use of standard of
care antibiotics in hospitals. These therapies could impact both the clinical results and use of our products being developed for hospital
acquired pneumonia.
Many
of our competitors, either alone or with their strategic collaborators, have substantially greater financial, technical and human resources
than we do and significantly greater experience in the discovery and development of drugs, obtaining FDA and other regulatory approvals,
and the commercialization of those products. Accordingly, our competitors may be more successful in obtaining approval for drugs and
achieving widespread market acceptance. Our competitors’ drugs may be more effective, or more effectively marketed and sold, than
any drug we may commercialize and may render our product candidates obsolete or non-competitive before we can recover the significant
expenses of developing and commercializing any of our product candidates. We anticipate that we will face intense and increasing competition
as new drugs enter the market and advanced technologies become available.
We
also compete with other clinical-stage companies and institutions for clinical trial participants, which could reduce our ability to
recruit participants for our clinical trials. Delay in recruiting clinical trial participants could adversely affect our ability to bring
a product to market prior to our competitors. Further, research and discoveries by others may result in breakthroughs that render our
product candidates obsolete even before they begin to generate any revenue.
In
addition, our competitors may obtain patent protection or FDA approval and commercialize products more rapidly than we do, which may
impact future sales of any of our product candidates that receive marketing approval. If the FDA approves the commercial sale of any
of our product candidates, we will also be competing with respect to marketing capabilities and manufacturing efficiency, areas in which
we have limited or no experience. We expect competition among products will be based on product efficacy and safety, the timing and scope
of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement coverage by government
and private third-party payors, and patent position. Our profitability and financial position will suffer if our products receive regulatory
approval but cannot compete effectively in the marketplace.
If
any of our product candidates are approved and commercialized, we may face competition from biosimilars. The route to market for biosimilars
was established with the passage of the Patient Protection and Affordable Care Act, or PPACA, in March 2010, providing 12 years of marketing
exclusivity for reference products and an additional six months of exclusivity if pediatric studies are conducted. In the EU, the EMA
has issued guidelines for approving products through an abbreviated pathway, and biosimilars have been approved. If a biosimilar version
of one of our potential products were approved in the U.S. or EU, it could have a negative effect on sales and gross profits of the potential
product and our financial condition.
Even
if we achieve market acceptance for our products, we may experience downward pricing pressure on the price of our drugs because of generic
and biosimilar competition and social pressure to lower the cost of drugs.
Several
of the FDA approved products for infectious diseases face patent expiration in the next several years. As a result, generic versions
and biosimilars of these drugs and biologicals may become available. We expect to face competition from these products, including price-based
competition. Pressure from government and private reimbursement groups, plus patient awareness and other social activist groups to reduce
drug prices may also put downward pressure on the prices of drugs, including our product candidates, if they are commercialized. Also,
if a biosimilar to any of our product candidates is approved by regulatory agencies, there will be significant pricing pressure on our
products, causing us or our collaborators to reduce the sales price of our products.
Our
product candidates may not be accepted in the marketplace; therefore, we may not be able to generate significant revenue, if any.
Even
if our product candidates are approved for sale, physicians and the medical community may not ultimately use them or may use them only
in applications more restricted than we expect. Our product candidates, if successfully developed, will compete with a number of traditional
products, including antibiotics, and immunotherapies manufactured and marketed by major pharmaceutical and other biotechnology companies.
Our product candidates will also compete with new products currently under development by such companies and others. Physicians will
prescribe a product only if they determine, based on experience, clinical data, side effect profiles, reimbursement for their patients
and other factors, that it is beneficial as compared to other products currently in use. Furthermore, physicians have been prescribing
traditional antibiotics for decades and may be resistant to switching to new, less established therapies. Many other factors influence
the adoption of new products, including marketing and distribution restrictions, course of treatment, adverse publicity, product pricing,
the views of thought leaders in the medical community and reimbursement by government and private third-party payors.
Risks
Relating to our Reliance on Third Parties
We
rely on third parties to conduct our preclinical studies and our clinical trials and to store and distribute our products for the clinical
trials we conduct. If these third parties do not perform as contractually required or expected, we may not be able to obtain regulatory
approval for our product candidates, or we may be delayed in doing so.
We
often rely on third parties, such as CROs, medical institutions, academic institutions, clinical investigators and contract laboratories,
to conduct our preclinical studies and clinical trials. We are responsible for confirming that our preclinical studies are conducted
in accordance with applicable regulations and that each of our clinical trials is conducted in accordance with its general investigational
plan and protocol. The FDA requires us to comply with Good Laboratory Practice for conducting and recording the results of our preclinical
studies and Good Clinical Practices, or GCP, for conducting, monitoring, recording and reporting the results of clinical trials, to ensure
that data and reported results are accurate and that the clinical trial participants are adequately protected. Our reliance on third
parties does not relieve us of these responsibilities. If the third parties conducting our clinical trials do not perform their contractual
duties or obligations, do not meet expected deadlines, fail to comply with GCP, do not adhere to our clinical trial protocols or otherwise
fail to generate reliable clinical data, we may need to enter into new arrangements with alternative third parties and our clinical trials
may be more costly than expected or budgeted, extended, delayed or terminated or may need to be repeated, and we may not be able to obtain
regulatory approval for or commercialize the product candidate being tested in such trials.
Our
CROs are not our employees, and we are therefore unable to directly monitor whether or not they devote sufficient time and resources
to our clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors,
for whom they may also be conducting clinical trials or other product development activities that could harm our competitive position.
If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality
or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements,
or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval
for, or successfully commercialize, our therapeutic candidates. If any such event were to occur, our financial results and the commercial
prospects for our therapeutic candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.
If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. Further, switching or adding additional CROs involves additional costs and requires management
time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which could
materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our
CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will
not have a material adverse impact on our business, financial condition and prospects.
In
addition, our future clinical trials will require a sufficient number of test subjects to evaluate the safety and effectiveness of our
therapeutic candidates. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients,
we may be required to repeat such clinical trials, which would delay the regulatory approval process.
We
also rely on other third parties to store and distribute our products for the clinical trials that we conduct. Any performance failure
on the part of our distributors could delay clinical development or marketing approval of our therapeutic candidates or commercialization
of our products, if approved, producing additional losses and depriving us of potential product revenue.
We
may explore new strategic collaborations that may never materialize or may fail.
We
may, in the future, periodically explore a variety of new strategic collaborations in an effort to gain access to additional product
candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to
face significant competition in seeking appropriate strategic collaborators, and these strategic collaborations can be complicated and
time-consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We
are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties
associated with establishing strategic collaborations.
Risks
Relating to our Exposure to Litigation
We
are exposed to potential product liability or similar claims, and insurance against these claims may not be available to us at a reasonable
rate in the future.
Our
business exposes us to potential liability risks that are inherent in the testing, manufacturing and marketing of human therapeutic products.
Clinical trials involve the testing of product candidates on human subjects or volunteers under a research plan and carry a risk of liability
for personal injury or death to patients due to unforeseen adverse side effects, improper administration of the product candidate, or
other factors. Many of these patients are already seriously ill and are therefore particularly vulnerable to further illness or death.
We
believe we have adequate levels of clinical trial liability insurance for our domestic and international clinical trials. However, there
can be no assurance that we will be able to maintain such insurance or that the amount of such insurance will be adequate to cover claims.
We could be materially and adversely affected if we were required to pay damages or incur defense costs in connection with a claim outside
the scope of indemnity or insurance coverage, if the indemnity is not performed or enforced in accordance with its terms, or if our liability
exceeds the amount of applicable insurance. In addition, there can be no assurance that insurance will continue to be available on terms
acceptable to us, if at all, or that if obtained, the insurance coverage will be sufficient to cover any potential claims or liabilities.
Similar risks would exist upon the commercialization or marketing of any products by us or our collaborators.
Regardless
of their merit or eventual outcome, product liability claims may result in:
|
● |
decreased
demand for our product; |
|
● |
injury
to our reputation and significant negative media attention; |
|
● |
withdrawal
of clinical trial volunteers; |
|
● |
costs
of litigation; |
|
● |
distraction
of management; and |
|
● |
substantial
monetary awards to plaintiffs. |
Should
any of these events occur, it could have a material adverse effect on our business and financial condition.
Claims
for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us
and may reduce the amount of money available to the Company.
Our
certificate of incorporation provides that we will indemnify our directors to the fullest extent permitted by Delaware law.
In
addition, as permitted by Section 145 of the Delaware General Corporation Law, our bylaws provide that:
|
● |
we
may, in our discretion, indemnify other officers, employees and agents in those circumstances where indemnification is permitted
by applicable law; |
|
● |
we
are required to advance expenses, as incurred, to our directors and executive officers in connection with defending a proceeding,
except that such directors or executive officers shall undertake to repay such advances if it is ultimately determined that such
person is not entitled to indemnification; |
|
● |
we
will not be obligated pursuant to our bylaws to indemnify any director or executive officer in connection with any proceeding (or
part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding
was authorized by our Board of Directors, (iii) such indemnification is provided by us, in our sole discretion, pursuant to the powers
vested in the corporation under applicable law or (iv) such indemnification is required to be made pursuant to our amended and restated
bylaws; |
|
● |
the
rights conferred in our bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors,
officers, employees and agents and to obtain insurance to indemnify such persons; and |
|
● |
we
may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and
agents. |
As
a result, if we are required to indemnify one or more of our directors or executive officers, it may reduce our available funds to satisfy
successful third-party claims against us, may reduce the amount of money available to us and may have a material adverse effect on our
business and financial condition.
Risks
Relating to Regulation of Our Industry
The
biopharmaceutical industry is subject to significant regulation and oversight in the United States, in addition to approval of products
for sale and marketing. We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency,
health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully
complied, with such laws, we could face substantial penalties.
Healthcare
providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any future product candidates
we may develop and any product candidates for which we obtain marketing approval. In addition to FDA restrictions on marketing of biopharmaceutical
products, we are exposed, directly, or indirectly, through our customers, to broadly applicable fraud and abuse and other healthcare
laws and regulations that may affect the business or financial arrangements and relationships through which we would market, sell and
distribute our products. The laws that may affect our ability to operate include, but are not limited to:
The
federal Anti-Kickback Statute which prohibits any person or entity from, among other things, knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in-kind, to induce or reward either
the referring of an individual for, or the purchasing, leasing, ordering or arranging for the purchase, lease or order of any health
care item or service reimbursable, in whole or in part, under Medicare, Medicaid or any other federally financed healthcare program.
The term “remuneration” has been broadly interpreted to include anything of value. This statute has been interpreted to apply
to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other hand.
Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution,
the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases
or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases
meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability.
The
federal false claims and civil monetary penalty laws, including the Federal False Claims Act, which imposes significant penalties and
can be enforced by private citizens through civil qui tam actions, prohibits any person or entity from, among other things, knowingly
presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to the federal government, or knowingly making,
using or causing to be made, a false statement or record material to a false or fraudulent claim to avoid, decrease or conceal an obligation
to pay money to the federal government. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the Federal False Claims Act. As a result of a modification made by the
Fraud Enforcement and Recovery Act of 2009, a claim includes “any request or demand” for money or property presented to the
U.S. government. Further, manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to
government payors if they are deemed to “cause” the submission of false or fraudulent claims. Criminal prosecution is also
possible for making or presenting a false, fictitious or fraudulent claim to the federal government. Several pharmaceutical and other
health care companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that
the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted
because of marketing of the product for unapproved, and thus non-reimbursable, uses.
The
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, imposes criminal liability
for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly
and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare
offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact
or making any materially false, fictitious or fraudulent statements or representations, or making or using any false writing or document
knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment
for healthcare benefits, items or services.
HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations,
which impose certain requirements relating to the privacy, security, transmission and breach reporting of individually identifiable health
information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers and their
respective business associates that perform services for them that involve individually identifiable health information. HITECH also
created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,
and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the
federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions.
The
federal physician payment transparency requirements, sometimes referred to as the “Physician Payments Sunshine Act,” and
its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment
is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to
the United States Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to
physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership
and investment interests held by physicians and their immediate family members.
State
and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or
more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private
insurers.
State
laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry’s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation
and other remuneration provided to physicians and other healthcare providers, state and local laws that require the registration of pharmaceutical
sales representatives, and other federal, state and foreign laws that govern the privacy and security of health information or personally
identifiable information in certain circumstances, including state health information privacy and data breach notification laws which
govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each
other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.
Because
of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject
to challenge under one or more of these laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change
in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and
state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers,
which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.
Ensuring
that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly and time
consuming. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that
apply to us, we may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual
imprisonment, exclusion from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational
harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity
agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations,
any of which could adversely affect our ability to operate our business and our results of operations.
Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could have a material adverse effect on our business.
We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we have established, comply with federal
and state health-care fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized
activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws
and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict
or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which
could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct,
and the precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses
or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such
laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant
civil, criminal, and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from governmental funded
healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional
reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance
with these laws.
Health
care reform measures could adversely affect our business.
In
the United States and foreign jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and
proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue
to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs. In 2010, the PPACA was enacted,
which includes measures to significantly change the way health care is financed by both governmental and private insurers. Among the
provisions of the PPACA of greatest importance to the pharmaceutical and biotechnology industry are the following:
|
● |
an
annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned
among these entities according to their market share in certain government healthcare programs; |
|
● |
implementation
of the federal physician payment transparency requirements, sometimes referred to as the “Physician Payments Sunshine Act”; |
|
● |
a
licensure framework for follow-on biologic products; |
|
● |
a
new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
research, along with funding for such research; |
|
● |
establishment
of a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; |
|
● |
an
increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the
average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs
at 100% of the Average Manufacturer Price, or AMP; |
|
● |
a
new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and
biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; |
|
● |
extension
of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed
care organizations; |
|
● |
expansion
of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals
and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby
potentially increasing manufacturers’ Medicaid rebate liability; |
|
● |
a
new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers’
outpatient drugs to be covered under Medicare Part D; and |
|
● |
expansion
of the entities eligible for discounts under the Public Health program. |
Some
of the provisions of the PPACA have yet to be implemented, and there have been legal and political challenges to certain aspects of the
PPACA. During President Trump’s administration, he signed two executive orders and other directives designed to delay, circumvent,
or loosen certain requirements mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and
replace all or part of the PPACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 (“TCJA”)
includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual
mandate”. Congress may consider other legislation to repeal or replace elements of the PPACA.
Many
of the details regarding the implementation of the PPACA are yet to be determined, and at this time, the full effect that the PPACA would
have on our business remains unclear. In particular, there is uncertainty surrounding the applicability of the biosimilars provisions
under the PPACA to our product candidates. The FDA has issued several guidance documents, and withdrawn others, but no implementing regulations
on biosimilars have been adopted. A number of biosimilar applications have been approved over the past few years. It is not certain that
we will receive 12 years of biologics marketing exclusivity for any of our products. The regulations that are ultimately promulgated
and their implementation are likely to have considerable impact on the way we conduct our business and may require us to change current
strategies. A biosimilar is a biological product that is highly similar to an approved drug notwithstanding minor differences in clinically
inactive components, and for which there are no clinically meaningful differences between the biological product and the approved drug
in terms of the safety, purity, and potency of the product.
Individual
states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access,
and marketing cost disclosure and transparency measures, and to encourage importation from other countries and bulk purchasing. Legally
mandated price controls on payment amounts by third-party payors or other restrictions could harm a pharmaceutical manufacturer’s
business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals
are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other healthcare programs. This could reduce ultimate demand for certain products or put pressure on product pricing, which
could negatively affect a pharmaceutical manufacturer’s business, results of operations, financial condition and prospects.
In
addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state
legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare
and Medicaid programs. While we cannot predict the full outcome of any such legislation, it may result in decreased reimbursement for
drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm our ability
to generate revenues. Increases in importation or re-importation of pharmaceutical products from foreign countries into the United States
could put competitive pressure on our ability to profitably price our products, which, in turn, could adversely affect our business,
results of operations, financial condition and prospects. We might elect not to seek approval for or market our products in foreign jurisdictions
in order to minimize the risk of re-importation, which could also reduce the revenue we generate from our product sales. It is also possible
that other legislative proposals having similar effects will be adopted.
Furthermore,
regulatory authorities’ assessment of the data and results required to demonstrate safety and efficacy can change over time and
can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency
funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable
to our business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety
of factors, including budget and funding levels and statutory, regulatory and policy changes.
Risks
Relating to Protecting our Intellectual Property
If
we are unable to protect our proprietary rights or to defend against infringement claims, we may not be able to compete effectively or
operate profitably.
Our
success will depend, in part, on our ability to obtain patents, operate without infringing the proprietary rights of others and maintain
trade secrets or other proprietary know-how, both in the United States and other countries. Patent matters in the biotechnology and pharmaceutical
industries can be highly uncertain, can involve changes in laws or regulations, and involve complex legal and factual questions. Accordingly,
the issuance, validity, breadth and enforceability of our patents and the existence of potentially blocking patent rights of others cannot
be predicted with any degree of certainty, either in the United States or in other countries.
Obtaining,
maintaining, and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable
patent applications, or maintain, enforce and/or license patents that may issue based on our patent applications, at a reasonable cost
or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before
it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing
and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties
and are reliant on our licensors or licensees. Further, although we enter into non-disclosure and confidentiality agreements with parties
who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside
scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any
of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our
ability to seek patent protection.
There
can be no assurance that we will discover or develop patentable products or processes or that patents will issue from any of the currently
pending patent applications or that claims granted on issued patents will be sufficient to protect our technologies, processes, or adequately
cover the actual products we may actually sell. Potential competitors or other researchers in the field may have filed patent applications,
been issued patents, published articles or otherwise created prior art that could restrict or block our efforts to obtain additional
patents or act as obstacles to our pending patent applications. There also can be no assurance that our issued patents or pending patent
applications, if issued, will not be challenged, invalidated, rendered unenforceable or not infringed, or that the rights granted thereunder
will provide us with proprietary protection or competitive advantages. We may not be aware of all third-party intellectual property rights
potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property
rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property
upon our freedom to operate, is highly uncertain. Patent applications in the U.S. and other jurisdictions are typically not published
until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make
the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such
inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.
Our patents or pending patent applications may be challenged in the courts or patent offices in the U.S. and abroad. For example, we
may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in post-grant
review procedures, oppositions, derivations, reexaminations, inter partes review or interference proceedings, in the U.S. or elsewhere,
challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity
or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others
from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology
and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such candidates might expire before or shortly after such candidates are commercialized. The patent position of biopharmaceutical
companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much
litigation, resulting in court decisions, including Supreme Court decisions, that have increased uncertainties as to the ability to enforce
patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of
the U.S., or vice versa. Our patent rights also depend on our compliance with technology and patent licenses upon which our patent rights
are based and upon the validity of assignments of patent rights from consultants and other inventors that were, or are, not employed
by us.
In
addition, competitors may manufacture and sell our potential products in those foreign countries where we have not filed for patent protection
or where patent protection may be unavailable, not obtainable or ultimately not enforceable or meaningful. In addition, even where patent
protection is obtained, third-party competitors may challenge our patent claims in the various patent offices, for example via opposition
in the European Patent Office or reexamination or interference proceedings in the United States Patent and Trademark Office, or USPTO,
or find ways to design around our patents by producing competitive non-infringing alternative products. The ability of such competitors
to sell such products in the United States or in foreign countries where we have obtained patents is usually governed by the patent laws
of the countries in which the product is sold.
We
will incur significant ongoing expenses in maintaining our patent portfolio in addition to maintaining other registered intellectual
property such as trademarks and copyrights. Maintaining registered intellectual property such as patents and trademarks requires timely
filing certain maintenance documents and paying certain maintenance fees, the failure of which could result in abandonment or cancellation
of such registered intellectual property. Should we lack the funds to maintain our patent portfolio or other registered intellectual
property, or to enforce our rights against infringers, we could be adversely impacted. Even if we succeed in enforcing one of our patents
against a third-party in a claim of infringement, any such action could divert the time and attention of management and impair our ability
to access additional capital and/or cost us significant funds.
If
we cannot meet requirements under our license and sublicense agreements, we could lose the rights to our products, which could have a
material adverse effect on our business.
We
depend on licensing and sublicensing agreements with third parties such as the University of Chicago, University of Iowa, Brigham and
Women’s Hospital, Inc., Brigham Young University, Public Health Service, Kenta Biotech Ltd., Massachusetts Institute of Technology-Broad
Institute, University of Alabama at Birmingham Research Foundation, and Medimmune Ltd. to maintain the intellectual property rights to
certain of our product candidates. These agreements require us to make payments and satisfy performance obligations in order to maintain
our rights under these agreements. All of these agreements last either throughout the life of the patents that are the subject of the
agreements, or with respect to other licensed technology, for a number of years after the first commercial sale of the relevant product.
If we fail to comply with the obligations under our license agreements or use the intellectual property licensed to us in an unauthorized
manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreements are
terminated, we may not be able to develop, manufacture, market or sell the products covered by our agreements and those being tested
or approved in combination with such products. Such an occurrence could materially adversely affect the value of the product candidate
being developed under any such agreement and any other product candidates being developed or tested in combination.
In
addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents
licensed to us. If we do not meet our obligations under our license agreements in a timely manner, or use the intellectual property licensed
to us in an unauthorized manner, we could be required to pay damages and we could lose the rights to our proprietary technology if our
licensor terminated the license. If our license agreements are terminated, we may not be able to develop, manufacture, market or sell
the products covered by our agreements and any being tested or approved in combination with such products. Such an occurrence could have
a material adverse effect on our business, results of operations and financial condition.
Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.
The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:
|
● |
others
may be able to make compounds that are similar to our product candidates but that are not covered by the claims of the patents that
we own or have exclusively licensed; |
|
● |
we
or our licensors or strategic collaborators might not have been the first to make the inventions covered by the issued patent or
pending patent application that we own or have exclusively licensed; |
|
● |
we
or our licensors or strategic collaborators might not have been the first to file patent applications covering certain of our inventions; |
|
● |
others
may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
property rights; |
|
● |
it
is possible that our pending patent applications will not lead to issued patents; |
|
● |
issued
patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable,
as a result of legal challenges by our competitors; |
|
● |
our
competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
learned from such activities to develop competitive products for sale in our major commercial markets; |
|
● |
we
may not develop additional proprietary technologies that are patentable; and |
|
● |
the
patents of others may have an adverse effect on our business. |
Should
any of these events occur, they could significantly harm our business, results of operations and prospects.
Patent
reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of our issued patents.
Changes
in either the patent laws or interpretation of the patent laws in the United States and Ex-US could increase the uncertainties and costs.
Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith
Act, signed into law in the United States on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant
changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide
more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission
of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered
post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. After March 2013, under the Leahy-Smith
Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met,
the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was
the first to invent the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs
surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have
a material adverse effect on our business, financial condition, results of operations and prospects.
The
U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain
circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S.
courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable
ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
We
may be subject to litigation with respect to the ownership and use of intellectual property that will be costly to defend or pursue and
uncertain in its outcome.
Our
success also will depend, in part, on our refraining from infringing patents or otherwise violating intellectual property owned or controlled
by others. There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and
we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect
to our products candidates, including interference proceedings before the U.S. Patent and Trademark Office. Pharmaceutical companies,
biotechnology companies, universities, research institutions and others may have filed patent applications or have received, or may obtain,
issued patents in the United States or elsewhere relating to aspects of our technology, and it may not always be clear to industry participants,
including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by
the courts, and the interpretation is not always uniform. Third parties may allege that we have infringed or misappropriated their intellectual
property. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either
do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able
to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing
evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur
substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings,
which could have a material adverse effect on us. In addition, we may not have sufficient resources to bring these actions to a successful
conclusion.
Litigation
or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive
and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting
our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially
increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution
activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater
financial resources and more mature and developed intellectual property portfolios.
If
we are found to infringe a third-party’s intellectual property rights, we could be forced, including by court order, to cease developing,
manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from
such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product
candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able
to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition,
we could be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed
a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business
operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets
of third parties could have a similar negative impact on our business.
It
is uncertain whether the issuance of any third-party patents will require us to alter our products or processes, obtain licenses, if
such licenses are available on commercially reasonable terms, or cease certain activities completely. Some third-party applications or
patents may conflict with our issued patents or pending applications. Any such conflict could result in a significant reduction of the
scope or value of our issued or licensed patents.
In
addition, if patents issued to other companies contain blocking, dominating or conflicting claims and such claims are ultimately determined
to be valid, we may be required to obtain licenses to these patents or to develop or obtain alternative non-infringing technology and
cease practicing those activities, including potentially manufacturing or selling any products deemed to infringe those patents. If any
licenses are required, there can be no assurance that we will be able to obtain any such licenses on commercially favorable terms, if
at all, and if these licenses are not obtained, we might be prevented from pursuing the development and commercialization of certain
of our potential products. Our failure to obtain a license to any technology that we may require to commercialize our products on favorable
terms may have a material adverse impact on our business, financial condition and results of operations.
Litigation,
which could result in substantial costs to us (even if determined in our favor), may also be necessary to enforce any patents issued
or licensed to us or to determine the scope and validity of the proprietary rights of others, or to defend against any accusations from
third parties that our products or activities are infringing their intellectual property rights. The FDA has only recently published
draft guidance documents for implementation of the Biologics Price Competition and Innovation Act, or BPCIA under the PPACA, related
to the development of follow-on biologics (biosimilars), and detailed guidance for patent litigation procedures under this act has not
yet been provided. If another company files for approval to market a competing follow-on biologic, and/or if such approval is given to
such a company, we may be required to promptly initiate patent litigation to prevent the marketing of such biosimilar version of our
product prior to the normal expiration of the patent. There can be no assurance that our issued or licensed patents would be held valid
by a court of competent jurisdiction or that any follow-on biologic would be found to infringe our patents.
In
addition, if our competitors file or have filed patent applications in the United States that claim technology also claimed by us, we
may have to participate in interference proceedings to determine priority of invention. These proceedings, if initiated by the USPTO,
could result in substantial costs to us, even if the eventual outcome is favorable to us. Such proceedings can be lengthy, are costly
to defend and involve complex questions of law and fact, the outcomes of which are difficult to predict. Moreover, we may have to participate
in post-grant proceedings or third-party ex parte or inter partes reexamination proceedings under the USPTO. An adverse
outcome with respect to a third-party claim or in an interference proceeding could subject us to significant liabilities, require us
to license disputed rights from third parties, or require us to cease using such technology, any of which could have a material adverse
effect on our business, financial condition and results of operations.
We
may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming
and unsuccessful.
Competitors
may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may
be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management
and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against
us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or
both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable,
in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk
that, even if the validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do
not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention.
An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties
or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive
products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.
Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable,
or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we
could ultimately be forced to cease use of such trademarks.
Even
if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only
monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments.
If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares
of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue
such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the
monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit
we receive as a result of the proceedings.
We
may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.
We
also rely on trade secrets to protect technology, especially where patent protection is not believed to be appropriate or obtainable
or where patents have not been issued. For example, our manufacturing process involves a number of trade secret steps, processes, and
conditions. Trade secrets and know-how can be difficult to protect. We attempt to protect our proprietary technology and processes, in
part, with confidentiality agreements and assignment of invention agreements with our employees and confidentiality agreements with our
consultants and certain contractors. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary
information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Any disclosure, either
intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants
and vendors that we engage to perform research, clinical studies or manufacturing activities, or misappropriation by third parties (such
as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our
technological achievements, thus eroding our competitive position in our market.
Enforcing
a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome
is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have
no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed
to or independently developed by a competitor or other third-party, our competitive position would be harmed.
There
can be no assurance that these agreements are valid and enforceable, will not be breached, that we would have adequate remedies for any
breach, or that our trade secrets will not otherwise become known or be independently discovered by competitors. We may fail in certain
circumstances to obtain the necessary confidentiality agreements or assignment of invention agreements, or their scope or term may not
be sufficiently broad to protect our interests or transfer adequate rights to us.
If
our trade secrets or other intellectual property become known to our competitors, it could result in a material adverse effect on our
business, financial condition and results of operations. To the extent that we or our consultants or research collaborators use intellectual
property owned by others in work for us, disputes may also arise as to the rights to related or resulting know-how and inventions.
The
patent protection and patent prosecution for some of our product candidates is dependent or may be dependent in the future on third parties.
While
we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when platform
technology patents or product-specific patents that relate to our product candidates are controlled by our licensors. In addition, our
licensors and/or licensees may have back-up rights to prosecute patent applications in the event that we do not do so or choose not to
do so, and our licensees may have the right to assume patent prosecution rights after certain milestones are reached. If any of our licensing
collaborators fails to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our
ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors
from making, using and selling competing products.
We
may not be able to protect our intellectual property rights throughout the world.
Patents
are of national or regional effect, and filing, prosecuting and defending patents on all of our product candidates throughout the world
would be prohibitively expensive. As such, we may not be able to prevent third parties from practicing our inventions in all countries
outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.
Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and
other intellectual property protection, particularly those relating to pharmaceuticals or biologics, which could make it difficult for
us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. In addition,
certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to
grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we
or our licensors are compelled to grant a license to a third-party, which could materially diminish the value of those patents. This
could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world
may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
Patent
rights are of limited duration. Given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering
our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or
generic products. A patent term extension based on regulatory delay may be available in the U.S. However, only a single patent can be
extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection
during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product
as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to
obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable
deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable
to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we
will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products
following our patent expiration, and our revenue could be reduced, possibly materially.
We
may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming
ownership of what we regard as our own intellectual property.
Some
of our employees and our licensors’ employees, including our senior management, were previously employed at universities or at
other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees may have
executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment.
Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may
be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such third-party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims,
in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual
property rights could be awarded to a third-party, and we could be required to obtain a license from such third-party to commercialize
our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management.
In
addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related
to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims,
litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.
Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic
maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime
of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured
by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure
to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal
documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would
be adversely affected.
Risks
Related to this Offering and Our Securities
Our 10% or more
stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters
subject to stockholder approval.
As
of March 31, 2023, our executive officers, directors and 10% or more stockholders, together with their respective affiliates, beneficially
owned approximately 18% of our outstanding securities. Accordingly, this group of security holders will be able to exert a significant
degree of influence over our management and affairs and over matters requiring security holder approval, including the election of our
Board of Directors, future issuances of our securities, declaration of dividends and approval of other significant corporate transactions.
This concentration of ownership could have the effect of delaying or preventing a change-of-control of the Company or otherwise discouraging
a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market
value of our securities. In addition, this significant concentration of share ownership may adversely affect the trading price for our
common stock if investors perceive disadvantages in owning stock in a company with such concentrated ownership.
Our ability to
use our net operating loss carry-forwards and certain other tax attributes is limited by Sections 382 and 383 of the Internal Revenue
Code.
Net
operating loss carryforwards allow companies to use past year net operating losses to offset against future years’ profits,
if any, to reduce future tax liabilities. Sections 382 and 383 of the Internal Revenue Code of 1986 limit a corporation’s
ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future
taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year period.
State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. An ownership change can therefore
result in significantly greater tax liabilities than a corporation would incur in the absence of such a change and any increased liabilities
could adversely affect the corporation’s business, results of operations, financial condition and cash flow.
Ownership
changes may occur in the future as a result of additional equity offerings or events over which we will have little or no control, including
purchases and sales of our equity by our five percent security holders, the emergence of new five percent security holders,
redemptions of our securities or certain changes in the ownership of any of our five percent security holders.
U.S. federal income
tax reform could adversely affect us.
On
December 22, 2017, President Trump signed into law the “Tax Cuts and Jobs Act,” or TCJA, that significantly reforms the Internal
Revenue Code of 1986, as amended. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional
limitations on the deductibility of interest, allows for the expensing of capital expenditures, a reduction to the maximum deduction
allowed for net operating losses generated in tax years after December 31, 2017, and puts into effect the migration from a “worldwide”
system of taxation to a partially territorial system. We do not expect tax reform to have a material impact to our projection of minimal
cash taxes or to our net operating losses. Our net deferred tax assets and liabilities will be revalued at the newly enacted U.S. corporate
rate, and the impact will be recognized in our tax expense in the year of enactment. Further, any eligibility we may have or may
someday have for tax credits associated with the qualified clinical testing expenses arising out of the development of orphan drugs will
be reduced to 25% as a result of the TCJA; thus, our net taxable income may be affected. We continue to examine the impact this tax reform
legislation may have on our business. The impact of this tax reform on holders of our common stock is uncertain and could be adverse.
This prospectus does not discuss any such tax legislation or the manner in which it might affect purchasers of our
common stock. We urge our stockholders, to consult with their legal and tax advisors with respect to such legislation and the potential
tax consequences of investing in our common stock.
Our common stock
is currently traded on the OTC Markets Pink Sheets, which may have an unfavorable impact on our stock price and liquidity.
Our
common stock is currently quoted on the OTC Markets Pink Sheets. The OTC Markets Pink Sheets is significantly more limited market than
the national securities exchanges such as the New York Stock Exchange, or Nasdaq stock exchange, and there are lower financial or qualitative
standards that a company must meet to have its stock quoted on the OTC Markets Pink Sheets. OTC Markets Pink Sheets is an inter-dealer
quotation system much less regulated than the major exchanges, and trading in our common stock may be subject to abuses, volatility and
shorting, which may have little to do with our operations or business prospects. This volatility could depress the market price of our
common stock for reasons unrelated to operating performance. The Financial Industry Regulatory Authority (“FINRA”) has adopted
rules that require a broker-dealer to have reasonable grounds for believing an investment is suitable for that customer when recommending
an investment to a customer. FINRA believes that there is a high probability that speculative low-priced securities will not be suitable
for some customers and may make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may
result in a limited ability to buy and sell our stock.
Our
common stock may be categorized as “penny stock,” which may make it more difficult for investors to sell their shares of
common stock due to suitability requirements.
Our
common stock may be categorized as “penny stock.” The Commission has adopted Rule 15g-9 under the Exchange Act, which generally
defines “penny stock” to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise
price of less than $5.00 per share, subject to certain exceptions. The price of our common stock is significantly less than $5.00 per
share and, unless we qualify for an exception, may be considered “penny stock.” This designation imposes additional sales
practice requirements on broker-dealers who sell to persons other than established customers and accredited investors. The penny stock
rules, if applicable to us, would require a broker-dealer buying our securities to disclose certain information concerning the transaction,
obtain a written agreement from the purchaser and determine that the purchaser is reasonably suitable to purchase the securities given
the increased risks generally inherent in penny stocks. These rules may restrict the ability and/or willingness of brokers or dealers
to buy or sell our common stock, either directly or on behalf of their clients, may discourage potential stockholders from purchasing
our common stock, or may adversely affect the ability of stockholders to sell their shares.
Financial
Industry Regulatory Authority (“FINRA”) sales practice requirements may also limit a stockholder’s ability to buy and
sell our common stock, which could depress the price of our common stock.
FINRA
has adopted rules that require a broker-dealer to have reasonable grounds for believing that the investment is suitable for that customer
before recommending an investment to a customer. Prior to recommending speculative low-priced securities to their non-institutional customers,
broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment
objectives, and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative
low-priced securities will not be suitable for at least some customers. Thus, the FINRA requirements make it more difficult for broker-dealers
to recommend that their customers buy our common stock, which may limit your ability to buy and sell our shares of common stock, have
an adverse effect on the market for our shares of common stock, and thereby depress our price per share of common stock.
Since
our common stock is currently quoted on the OTC Markets Pink Sheets our stockholders may face significant restrictions on the resale of our
common stock due to state “blue sky” laws and the sale of common stock in this offering is subject to state “blue sky”
laws.
Each
state has its own securities laws, often called “blue sky” laws, which (i) limit sales of securities to a state’s residents
unless the securities are registered in that state or qualify for an exemption from registration, and (ii) govern the reporting requirements
for broker-dealers doing business directly or indirectly in the state. Before a security is sold in a state, there must be a registration
in place to cover the transaction, or the transaction must be exempt from registration. The applicable broker must also be registered
in that state. Since our common stock is currently quoted on the OTC Markets Pink Sheets, a determination regarding registration will be made
by those broker-dealers, if any, who agree to serve as the market-makers for our common stock. There may be significant state blue sky
law restrictions on the ability of investors to sell, and on purchasers to buy, our common stock and warrants. You should therefore consider
the resale market for our common stock and warrants to be limited, as you may be unable to resell your common stock without the significant
expense of state registration or qualification.
This
is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe
is required for our business plan, including our near-term business plan.
The
placement agent has agreed to use its reasonable
best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation to buy any of the
securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no
required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering
amount required as a condition to the closing of this offering, the actual offering amount, placement agent fees and proceeds
to us are not presently determinable and may be substantially less than the maximum amounts set forth herein. We may sell fewer than
all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering
will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including
our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term
and may need to raise additional funds to complete such short-term operations. Such additional fundraises may not be available or available
on terms acceptable to us.
Our
management will have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways
with which you do not agree and in ways that may not yield a return.
Our
management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described
in the section titled “Use of Proceeds,” and you will not have the opportunity as part of your investment decision to assess
whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of
the net proceeds from this offering, their ultimate use may vary from their currently intended use. The failure by our management to
apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in investment-grade,
interest-bearing securities. These investments may not yield a favorable return to our securityholders.
If
you purchase common stock in this offering, you will suffer immediate dilution of your investment.
You
will incur immediate and substantial dilution as a result of this offering. Because the price per share of our common stock being offered
is higher than the net tangible book value per share of our common stock, you will experience dilution to the extent of the difference
between the offering price per share of common stock you pay in this offering and the net tangible book value per share of our common
stock immediately after this offering. Our net tangible book value as of March 31, 2023, was approximately $(29.2) million,
or approximately $(0.81) per share of common stock. Net tangible book value per share is equal to our total tangible assets minus
total liabilities, all divided by the number of shares of common stock outstanding. See the section titled “Dilution” for
a more detailed discussion of the dilution you will incur if you purchase securities in this offering.
The
price of our common stock may fluctuate substantially.
You
should consider an investment in our common stock to be risky, and you should invest in our common stock only if you can withstand a
significant loss and wide fluctuations in the market value of your investment. Some factors that may cause the market price of our common
stock to fluctuate, in addition to the other risks mentioned in this “Risk Factors” section, are:
|
● |
sale
of our common stock by our stockholders, executives, and directors; |
|
● |
volatility
and limitations in trading volumes of our shares of common stock; |
|
● |
our
ability to obtain financings to conduct and complete research and development activities including, but not limited to, our human
clinical trials, and other business activities; |
|
● |
our
announcements or our competitors’ announcements regarding new products or services, enhancements, significant contracts, acquisitions
or strategic investments; |
|
● |
failures
to meet external expectations or management guidance; |
|
● |
clinical
trial progress and outcomes; |
|
● |
changes
in our capital structure or dividend policy; |
|
● |
our
cash position and substantial doubt about our ability to continue as a going concern; |
|
● |
announcements
and events surrounding financing efforts, including debt and equity securities; |
|
● |
our
inability to enter into new markets or develop new products; |
|
● |
reputational
issues; |
|
● |
announcements
of acquisitions, partnerships, collaborations, joint ventures, new products, capital commitments, or other events by us or our competitors; |
|
● |
changes
in general economic, political and market conditions in any of the regions in which we conduct our business; |
|
● |
changes
in industry conditions or perceptions; |
|
● |
changes
in valuations of similar companies or groups of companies; |
|
● |
analyst
research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage; |
|
● |
departures
and additions of key personnel; |
|
● |
disputes
and litigations related to contractual obligations; |
|
● |
changes
in applicable laws, rules, regulations, or accounting practices and other dynamics; |
|
● |
catastrophic
weather and/or global disease outbreaks, such as the recent COVID-19 pandemic; and or |
|
● |
other
events or factors, many of which may be out of our control. |
Future sales and
issuances of our common stock or rights to purchase common stock pursuant to our equity incentive plan could result in additional dilution
of the percentage ownership of our stockholders and could cause our share price to fall.
We
expect that significant additional capital will be needed in the future to continue our planned operations, including expanding research
and development, funding clinical trials, purchasing of capital equipment, hiring new personnel, commercializing our products, and continuing
activities as an operating public company. To the extent we raise additional capital by issuing equity securities, our stockholders may
experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions
at prices and in a manner, we determine from time to time. If we sell common stock, convertible securities or other equity securities
in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution
to our existing stockholders, and new investors could gain rights superior to our existing stockholders.
We do not intend
to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.
We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate
declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase,
if any, of our share price.
If
you purchase our securities in this offering, you may experience future dilution as a result of future equity offerings or other equity
issuances.
In
order to raise additional capital, we believe that we will offer and issue additional shares of our common stock or other securities
convertible into or exchangeable for our common stock in the future. We cannot assure you that we will be able to sell shares or other
securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this
offering, and investors purchasing other securities in the future could have rights superior to existing stockholders. The price per
share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock
in future transactions may be higher or lower than the price per share in this offering.
In
addition, we have a significant number of warrants and stock options outstanding. To the extent that outstanding stock options or warrants
have been or may be exercised or other shares issued, you may experience further dilution. Further, we may choose to raise additional
capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans.
There
is no public market for the pre-funded warrants or warrants being offered in this offering.
There
is no established public trading market for the pre-funded warrants or warrants being offered in this offering, and we do not expect
a market to develop. In addition, we do not intend to apply to list the pre-funded warrants or warrants on any securities exchange or
nationally recognized trading system. Without an active market, the liquidity of the pre-funded
warrants and warrants will be limited.
Holders
of pre-funded warrants and common warrants purchased in this offering will have no rights as common stockholders until such holders
exercise such warrants and acquire our common stock, except as set forth in the pre-funded warrants and common warrants.
Until
holders of pre-funded warrants or warrants acquire shares of our common stock upon exercise of such warrants, holders of pre-funded warrants
or warrants will have no rights with respect to the shares of our common stock underlying such warrants. Upon exercise of the pre-funded
warrants or warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record
date occurs after the exercise date.
We
are an “emerging growth company” and will be able to avail ourselves of reduced disclosure requirements applicable to emerging
growth companies, which could make our common stock less attractive to investors.
We
are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we
intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not “emerging growth companies” including not being required to comply with the auditor attestation requirements of Section
404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved. In addition, Section 107 of the JOBS Act also provides that an “emerging growth
company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying
with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We are electing to delay such adoption of new
or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for non-emerging growth companies. As a result of such election, our consolidated financial
statements may not be comparable to the financial statements of other public companies. We cannot predict if investors will find our
common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result,
there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these
reporting exemptions until we are no longer an “emerging growth company.” We will remain an “emerging growth company”
until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii)
the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (iii) the
date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we
are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission.
Because
we have elected to defer compliance with new or revised accounting standards, our financial statement disclosure may not be comparable
to similar companies.
We
have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of
the JOBS Act. This allows us to delay the adoption of new or revised accounting standards that have different effective dates for public
and private companies until those standards apply to private companies. As a result of our election, our consolidated financial statements
may not be comparable to companies that comply with public company effective dates.
Because
of this extended transition period, we may be less attractive to investors and it may be difficult for us to raise additional capital
as and when we need it. Investors may be unable to compare our business with other companies in our industry if they believe that our
financial accounting is not as transparent as other companies in our industry. If we are unable to raise additional capital as and when
we need it, our financial condition and results of operations may be materially and adversely affected.
We
may be at risk of securities class action litigation.
We
may be at risk of securities class action litigation. This risk is especially relevant for us due to our dependence on positive clinical
trial outcomes and regulatory approvals of each of our product candidates. In the past, biotechnology and pharmaceutical companies have
experienced significant stock price volatility, particularly when associated with binary events such as clinical trials and product approvals.
If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which
could harm our business and results in a decline in the market price of our common stock.
Our
management will be required to devote substantial time to compliance initiatives.
As
a public company, we incur significant legal, accounting, and other expenses that we did not incur as a newly formed entity. The Sarbanes-Oxley
Act, as well as rules subsequently implemented by the SEC and The Nasdaq Capital Market, have imposed various new requirements on public
companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate
governance practices. Our management and other personnel will need to devote a substantial amount of time to these new compliance initiatives.
Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time
consuming and costly. We expect these rules and regulations to make it more difficult and more expensive for us to obtain director and
officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage.
Upon
our dissolution, you may not recoup all or any portion of your investment.
In
the event of a liquidation, dissolution or winding-up of us, whether voluntary or involuntary, the proceeds and/or our assets may not
be sufficient to repay the aggregate investment you purchased in our company. In this event, you could lose some or all of your investment.
We
have identified a material weakness in our internal control over financial reporting. Failure to maintain effective internal controls
could cause our investors to lose confidence in us and adversely affect the market price of our common stock. If our internal controls
are not effective, we may not be able to accurately report our financial results or prevent fraud.
Effective
internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. In connection
with the preparation of our consolidated financial statements for the year ended December 31, 2022, we concluded that there was a material
weakness in our internal control over financial reporting related to the restatement described
elsewhere in this prospectus. A material weakness is a deficiency, or a combination of deficiencies, in internal control over
financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial
statements will not be prevented or detected on a timely basis.
In
the course of finalizing the audit of our financial statements for the year ended December 31, 2022, we with our independent auditors,
identified a misapplication of GAAP that resulted in a restatement. The restatement results from the Company’s correction of its
valuation using fair value option accounting of our Notes Payable. The correction reduces the valuation of the Notes Payable, which results
in recognizing Other Comprehensive Income in accordance with the requirements of ASC 820, Fair Value Measurement (“ASC 820”).
The correction in Notes Payable valuation using fair value option resulted in adjustments to Notes Payable - Current, Notes Payable –
Long Term, and Other Comprehensive Income. The Company evaluated the adjustments to the Notes Payable valuation recorded during 2022
and 2021, and, after assessing the materiality of such adjustments, is restating its financial statements for each of the quarterly periods
ended March 31, 2022, June 30, 2022 and September 30, 2022 in the 2022 Form 10-K for the year ended December 31, 2022 (collectively,
the “Prior Quarterly Financial Statements”). The Company concluded that the impact of the proposed accounting adjustments
on the Company’s unaudited condensed consolidated financial statements for each of the year end and quarterly periods ended December
31, 2021 were not material to those financial statements.
While
we have designed and implemented, or expect to implement, measures that we believe address or will address this control weakness, we
continue to develop our internal controls, processes and reporting systems by, among other things, hiring qualified personnel with expertise
to perform specific functions, and designing and implementing improved processes and internal controls, including ongoing senior management
review and audit committee oversight. We plan to remediate the identified material weakness by hiring financial consultants and expect
to hire additional senior accounting staff to complete the remediation by the end of 2023. We expect to incur additional costs to remediate
this weakness, primarily personnel costs and external consulting fees. We may not be successful in implementing these systems or in developing
other internal controls, which may undermine our ability to provide accurate, timely and reliable reports on our financial and operating
results. Further, we will not be able to fully assess whether the steps we are taking will remediate the material weakness in our internal
control over financial reporting until we have completed our implementation efforts and sufficient time passes in order to evaluate their
effectiveness. In addition, if we identify additional material weaknesses in our internal control over financial reporting, we may not
detect errors on a timely basis and our consolidated financial statements may be materially misstated. Moreover, in the future we may
engage in business transactions, such as acquisitions, reorganizations or implementation of new information systems that could negatively
affect our internal control over financial reporting and result in material weaknesses.
Our
independent registered public accounting firm did not perform an evaluation of our internal control over financial reporting during any
period in accordance with the provisions of the Sarbanes-Oxley Act. Had our independent registered public accounting firm performed an
evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional control
deficiencies amounting to material weaknesses might have been identified. If we identify new material weaknesses in our internal control
over financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner,
if we are unable to assert that our internal control over financial reporting is effective, or if our independent registered public accounting
firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, we may be late with the
filing of our periodic reports, investors may lose confidence in the accuracy and completeness of our financial reports and the market
price of our common stock could be negatively affected. As a result of such failures, we could also become subject to investigations
by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, and become subject to litigation
from investors and stockholders, which could harm our reputation, financial condition or divert financial and management resources from
our core business.
The
Restatement of the Prior Quarterly Financial Statements may affect investor confidence and raise reputational issues and may subject
us to additional risks and uncertainties, including increased professional costs and the increased possibility of legal proceedings.
As
discussed in Note 15, we reached a determination to restate our unaudited consolidated financial statements and related disclosures for
the periods disclosed in those notes after it was determined under ASC 820 that our Notes Payable were over-valued as they did not factor
credit risk into the fair value option valuation. As a result, the Company corrected the valuation of Notes Payable – Current and
Notes Payable – Long Term, which resulted in adjustments to Other Comprehensive Income. The Company evaluated the proposed
adjustments to the Notes Payable valuations recorded during 2022 and 2021, and, after assessing the materiality of such adjustments
under ASC 820, is restating its financial statements for each of the quarterly periods ended March 31, 2022, June 30, 2022 and September
30, 2022 in the 2022 Form 10-K for the year ended December 31, 2022 (collectively, the “Prior Quarterly Financial Statements”).
CAUTIONARY
NOTE CONCERNING FORWARD-LOOKING STATEMENTS
This
prospectus contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking
statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including
the reasons described in our “Prospectus Summary,” “Use of Proceeds,” “Risk Factors,” “Management
Discussion and Analysis of Financial Condition and Result of Operations,” and “Business” sections. In some cases, you
can identify these forward-looking statements by terms such as “anticipate,” “believe,” “continue,”
“could,” “depends,” “estimate,” “expects,” “intend,” “may,” “ongoing,”
“plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” or the negative of those terms or other similar expressions, although not all forward-looking statements contain
those words.
Our
operations and business prospects are always subject to risks and uncertainties including, among others:
|
● |
the
timing of regulatory submissions; |
|
|
|
|
● |
our
ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop,
and the labeling under any approval we may obtain; |
|
|
|
|
● |
approvals
for clinical trials may be delayed or withheld by regulatory agencies; |
|
|
|
|
● |
preclinical
and clinical studies will not be successful or confirm earlier results or meet expectations or meet regulatory requirements or meet
performance thresholds for commercial success; |
|
|
|
|
● |
risks
relating to the timing and costs of clinical trials, the timing and costs of other expenses; |
|
|
|
|
● |
risks
associated with obtaining third-party funding; |
|
|
|
|
● |
risks
associated with delays, increased costs and funding shortages caused by or resulting from the COVID-19 pandemic; |
|
|
|
|
● |
management
and employee operations and execution risks; |
|
|
|
|
● |
loss
of key personnel; |
|
|
|
|
● |
competition; |
|
|
|
|
● |
risks
related to market acceptance of products; |
|
|
|
|
● |
intellectual
property risks; |
|
|
|
|
● |
assumptions
regarding the size of the available market, benefits of our products, product pricing, timing of product launches; |
|
|
|
|
● |
risks
associated with the uncertainty of future financial results; |
|
|
|
|
● |
risks
associated with this offering; |
|
|
|
|
● |
our
ability to attract collaborators and partners; and |
|
|
|
|
● |
risks
associated with our reliance on third party organizations. |
The
forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events
and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point
in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely
on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus.
USE
OF PROCEEDS
We
estimate that the net proceeds from the sale of the securities offered under this prospectus, after deducting the placement agent’s
fees and estimated offering expenses payable by us, will be approximately $1.6 million (based on an assumed public offering price
per share and accompanying common warrant of $0.22 per share, which was the last reported sales price of our common stock on the
OTC Markets Pink Sheets on July 24, 2023 and an assuming offering amount of $2,000,000 in gross proceeds). However, because
this is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering, the
actual offering amount, the placement agent’s fees and net proceeds to us are not presently determinable and may be substantially
less than the maximum amounts set forth on the cover page of this prospectus.
We
intend to use the net proceeds to fund our planned clinical trials, manufacturing and process development, analytical testing, regulatory
expenses and for general corporate purposes, including working capital and repaying $495,000 on Note 1 on a monthly basis
starting in July 2023 and 16.667% of the outstanding balance on Note 2 monthly starting in October 2023. As of June 30, 2023,
approximately $11.0 million was owed to Streeterville under the Notes including accrued interest. The maturity date of the Notes
are November 2023 and April 2024.
In
the ordinary course of our business, we expect to from time to time evaluate the acquisition of, investment in or in-license of complementary
products, technologies or businesses, and we could use a portion of the net proceeds from this offering for such activities. We currently
do not have any agreements, arrangements or commitments with respect to any potential acquisition, investment or license.
This
expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts
and timing of our actual expenditures may vary significantly depending on numerous factors, including the status of and results from
clinical trials of our product candidates. As a result, our management will retain broad discretion over the allocation of the net proceeds
from this offering. We may find it necessary or advisable to use the net proceeds from this offering for other purposes, and we will
have broad discretion in the application of net proceeds from this offering. Furthermore, we anticipate that we will need to secure additional
funding for the further development of our product candidates or commercially launch our product candidates in the United States.
Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term, investment-grade, interest-bearing instruments and U.S. government securities.
DILUTION
If
you invest in our securities, your ownership interest will be diluted to the extent of the difference between the public offering
price per share of our common stock and accompanying common warrant and the as adjusted net tangible book value per share of our
common stock immediately after giving effect to this offering.
Our
net tangible book deficit as of March 31, 2023 was approximately $(29.2) million, or approximately $(0.81)
per share of common stock. Our net tangible book deficit is the amount of our total tangible assets less our liabilities. Net tangible
book deficit per share is our net tangible book deficit divided by the number of shares of common stock outstanding as of March
31, 2023.
After
giving effect to the assumed sale of 9,090,909 shares of common stock and accompanying common warrants in this offering at an
assumed public offering price of $0.22 per share (the last reported sale price of our common stock on the OTC Markets Pink Sheets
on July 24, 2023), and after deducting estimated placement agent fees and estimated offering expenses payable by us, and assuming
no sale of any pre-funded warrants in this offering, no exercise of the warrants being offered in this offering, that no value is attributed
to such warrants and that such warrants are classified as and accounted for as equity, our as adjusted net tangible book value as of
March 31, 2023 would have been approximately $(27.6) million, or approximately $(0.61) per share of common stock. This
amount represents an immediate increase in as adjusted net tangible book value of $0.20 per share to our existing stockholders
and an immediate dilution of $0.83 per share to investors participating in this offering. We determine dilution per share to investors
participating in this offering by subtracting as adjusted net tangible book value per share after giving effect to this offering from
the assumed public offering price per share and accompanying common warrant paid by investors participating in this offering.
Assumed public offering price per share and accompanying common warrant |
|
|
|
| |
$ | 0.22 | |
Historical
net tangible book value per share as of March 31, 2023 |
|
$ |
(0.81 |
) | |
| | |
Increase
in net tangible book value per share attributable to this offering |
|
$ |
0.20 |
| |
| | |
As
adjusted tangible book value per share, after giving effect to this offering |
|
|
|
| |
$ | (0.61 | ) |
Dilution
per share to investors in this offering |
|
|
|
| |
$ | 0.83 | |
The
number of shares of our common stock that will be outstanding after this offering is based on 36,077,532 shares of or common stock
outstanding as of March 31, 2023, and excludes:
|
● |
2,102,944
shares of our common stock issuable upon the
exercise of options to purchase shares of our common stock outstanding as of March 31, 2023, with a weighted-average exercise
price of $7.35 per share; |
|
|
|
|
● |
325,540
shares of our common stock issuable upon the
vesting of restricted stock units outstanding as of March 31, 2023, with a weighted-average grant price of $0.95 per share; |
|
|
|
|
● |
10,742,404
shares of our common stock issuable upon the exercise of warrants to purchase common stock outstanding as of March 31, 2023, with
a weighted-average exercise price of $2.31 per share; |
|
|
|
|
● |
55,074
shares of our common stock reserved for future
issuance under our stock incentive plans. |
The
information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering
determined at pricing. Except as indicated otherwise, the discussion and table above assume (i) no sale of pre-funded warrants, which,
if sold, would reduce the number of shares of common stock that we are offering on a one-for-one basis and (ii) no exercise of the common
warrants being sold in this offering.
MANAGEMENT’s
DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Restatement
and Revision of Previously Issued Consolidated Financial Information
In
this “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” we have restated
our previously issued unaudited condensed consolidated statements of operations for the three months ended March 31, 2022, for the three
and six months ended June 30, 2022 and for the three and nine months ended September 30, 2022; and condensed consolidated balance sheet
for the three months ended March 31, 2022, for the six months ended June 30, 2022 and for the nine months ended September 30, 2022 (the
“Prior Quarterly Financial Statements”), to reflect the restatement more fully described in Note 15 Restatement to the audited
consolidated financial statements included in this prospectus. Within this section, we revised our unaudited condensed consolidated financial
statements as of and for the three months ended March 31, 2022, the three and six months ended June 30, 2022, and the three and nine
months ended September 30, 2022.
The
financial information that has been previously filed or otherwise reported for the Prior Quarterly Financial Statements is superseded
by the information in this prospectus. See Note 15 Restatement in the notes to the audited consolidated financial statements included
in the prospectus for additional information on the restatement and the related financial statement impact.
Description
of Aridis Pharmaceuticals
We
are a late clinical development-stage biopharmaceutical company focused on the discovery and development of novel anti-infectives. A
significant focus of ours is on targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
mAbs represent an innovative treatment approach that harnesses the human immune system to fight infections and are designed to overcome
the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, limited tolerability,
negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. The majority of our product candidates
are derived by employing our differentiated antibody discovery platforms. Our proprietary product pipeline comprises fully human mAbs
targeting specific pathogens associated with life-threatening bacterial infections, primarily nosocomial pneumonia, and viral infections
such as COVID-19. Our proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life
threatening bacterial and viral infections, primarily hospital acquired pneumonia, or HAP, ventilator associated pneumonia, or VAP, cystic
fibrosis, and COVID-19. Our clinical stage product candidates have exhibited promising preclinical data and clinical data.
Our
ʎPEX™ production platform technology enables the screening of a large number of antibody-producing B-cells from patients and
generation of high mAb-producing mammalian production cell line at a speed not previously attainable. As a result, we can significantly
reduce time for antibody discovery and manufacturing compared to conventional approaches. This technology is being applied to the development
of COVID-19 mAbs.
Current
clinical development activities are focused on AR-301, AR-320, AR-501. Our lead product candidates, AR-301 and AR-320, target gram positive
bacteria S. aureus, a common pathogen associated with HAP, VAP, and a number of other life-threatening infections. AR-301 neutralizes
the alpha toxin produced by gram-positive bacteria S. aureus and prevents alpha toxin mediated destruction of host cells and host
immune response to the S. aureus infection. AR-301’s mode of action is independent of the antibiotic resistance profile
of S. aureus, and it is active against infections caused by both methicillin-resistant S. aureus (“MRSA”) and
methicillin-susceptible S. aureus (“MSSA”). AR-301 has exhibited promising data from a Phase 1/2a clinical study in
S. aureus VAP patients (n=48 patients), showing consistent trends toward clinical benefits. A global Phase 3 trial to evaluate
the therapeutic adjunctive treatment of AR-301 in S. aureus infected ventilator associated pneumonia patients has recently closed
patient enrollment. Primary outcome measures of safety and tolerability of AR-301 were achieved. Due to the limited sample size evaluated,
statistical significance was not reached for the primary endpoint of clinical cure rate on Day 21 compared to antibiotics alone. However,
in a prespecified older adults (>65 yrs) population, substantial improvement in the clinical cure rate of pneumonia that reached statistical
significance at day 28 post-treatment with AR-301. The trial represents the first of two Phase 3 superiority clinical studies evaluating
immunotherapy with a fully human mAb to treat acute pneumonia in the intensive care unit (ICU) setting.
AR-320
and AR-301 share similar targets and mechanism of action, thus are complementary products. AR-320 (also called ‘suvratoxumab’)
is being developed as a preventive treatment of S. aureus pneumonia, while AR-301 is being developed as a therapeutic treatment.
A multinational, randomized, double blinded, placebo -controlled Phase 2 study (n=196 patients) showed that mechanically ventilated ICU
patients colonized with S. aureus who are treated with AR-320 saw a relative risk reduction of pneumonia by 32% in the overall
intent to treat study population, and by 47% in the prespecified under 65-year-old population, which is the target population in the
planned Phase 3 study. The relative risk reduction in the target population reached statistical significance and was also associated
with a substantial reduction in the duration of care needed in the ICU and hospital.
On
March 20, 2023, we received written notice from MedImmune that it has terminated that certain License Agreement pursuant to Section 9.2.1
of the License Agreement for non-payment of the Upfront Cash Payment which was due on December 31, 2021. The notice states that such
termination shall be effective on March 30, 2023. As a result of the termination notice, the on-going AR-320-003 Phase 3 clinical study
has been put on hold. We do not agree that we are in material breach of the License Agreement.
Based
on the failure of MedImmune to assist in the necessary technology transfer pursuant to Section 3.5.2 of the License Agreement, we notified
MedImmune on March 24, 2023 that it was in material breach of Section 3.5.2 and requested that the material breach be cured as soon as
possible.
To
complement and diversify our portfolio of targeted mAbs, we are developing a broad-spectrum small molecule non-antibiotic anti-infective
agent gallium citrate (AR-501). AR-501 is being developed in collaboration with the Cystic Fibrosis Foundation (“CFF”) as
a chronic inhaled therapy to treat lung infections in cystic fibrosis patients. AR-501 was granted Orphan Drug, Fast Track and Qualified
Infectious Disease Product (“QIDP”) designations by the Food and Drug Administration (“FDA”) the European Medicines
Agency (“EMA”) granted the program Orphan Drug Designation. AR-501 is being evaluated in a Phase 1/2a for the treatment of
chronic lung infections associated with cystic fibrosis. In June 2020, we announced positive results from the Phase 1 portion of our
Phase 1/2a clinical trial of AR-501 in which healthy subjects were enrolled. The FDA reviewed the Phase 1 study results and agreed that
the study could proceed at all dose levels to the Phase 2a portion of the Phase 1/2a trial in adult subjects with cystic fibrosis (“CF”).
Based on available blinded safety data of the on-going Phase 2a study, FDA also recently agreed with the Company’s proposal to
include an additional higher dose cohort. The study’s primary and secondary endpoints of safety and pharmacokinetics (PK) were
met. Three weekly inhaled doses of AR-501 at 6.4mg, 20mg, and 40mg dose levels were well tolerated in CF patients. No drug related serious
adverse events (SAEs) were observed. The majority of treatment emergent adverse events (TEAEs) were respiratory in nature and mostly
mild to moderate in severity. CF patients achieved high uptake of AR-501 in the respiratory tract, as measured by sputum concentrations,
at levels that were >50-fold higher than required for inhibition of the target bacteria P. aeruginosa. Inhaled delivery achieved
more than 10-fold higher respiratory uptake of gallium (AR-501) than past clinical studies of intravenous (IV) gallium which resulted
in lung function improvement and P. aeruginosa reduction.
AR-701
is a cocktail of two fully human IgG1 mAbs discovered from screening the antibody secreting B-cells of convalescent SARS-CoV-2 infected
(COVID-19) patients. The AR-701 cocktail neutralizes coronaviruses (CoV) using a distinct mechanism of action, namely inhibition of viral
fusion and entry into human cells (AR-703) or blockage of virus binding to the human ‘ACE2’ receptor (AR-720). Each of the
mAbs conferred strong protection against Omicron BA.1 infected animals when given either parenterally or by intranasal administration.
On August 10, 2022, we announced that AR-701 was also shown to be effective in SARS-CoV-2 (COVID-19) infected macaque monkeys (non-human
primates) when administered by inhalation.
As
part of an ongoing grant from the Bill and Melinda Gates Foundation, we delivered proof-of-concept pre-clinical data to demonstrate prevention
of influenza and SARS-CoV2 viral transmission using our inhaled formulation technology.
To
date, we have devoted substantially all of our resources to research and development efforts relating to our therapeutic candidates,
including conducting clinical trials and developing manufacturing capabilities, in-licensing related intellectual property, protecting
our intellectual property and providing general and administrative support for these operations. We have generated revenue from our payments
under our collaboration strategic research and development contracts and federal awards and grants, as well as awards and grants from
not-for-profit entities and fee for service to third-party entities. Since our inception, we have funded our operations primarily through
these sources and the issuance of common stock, convertible preferred stock, and debt securities. Current clinical development activities
are focused on AR-301 and AR-501. Our expenses and resulting cash burn during the year ended December 31, 2022 and 2021, were largely
due to costs associated with the Phase 3 study of AR-301 for the treatment of VAP caused by the S. aureus bacteria, preclinical
development of AR-701 COVID-19 mAbs, the preparation of AR-320 for a phase 3 clinical trial that was be initiated in the first half of
2022 and the Phase 1/2a study of AR-501 for the treatment of chronic lung infections associated with cystic fibrosis.
Financial
Overview
We
have incurred losses since our inception. Our net losses were approximately $30.4 million and $42.2 million for the years ended December
31, 2022 and 2021, respectively. As of December 31, 2022 we had approximately $5.6 million of cash, cash equivalents and restricted cash
and had an accumulated deficit of approximately $195.7 million. Substantially all of our net losses have resulted from costs incurred
in connection with our research and development programs, clinical trials, intellectual property matters, strengthening our manufacturing
capabilities, and from general and administrative costs associated with our operations.
We
have not yet achieved commercialization of our products and have a cumulative net loss from our operations. We will continue to incur
net losses for the foreseeable future. Our consolidated financial statements have been prepared assuming that we will continue as a going
concern. We will require additional capital to meet our long-term operating requirements. We expect to raise additional capital through
the sale of equity and/or debt securities. Historically, our principal sources of cash have included proceeds from grant funding, fees
for services performed, issuances of debt and the sale of our common and preferred stock. Our principal uses of cash have included cash
used in operations. We expect that the principal uses of cash in the future will be for continuing operations, funding of research and
development including our clinical trials and general working capital requirements.
We
anticipate that our expenses will increase substantially if and as we:
● |
continue
enrollment in our ongoing clinical trials; |
● |
initiate
new clinical trials; |
● |
seek
to identify, assess, acquire and develop other products, therapeutic candidates and technologies; |
● |
seek
regulatory and marketing approvals in multiple jurisdictions for our therapeutic candidates that successfully complete clinical studies; |
● |
establish
collaborations with third parties for the development and commercialization of our products and therapeutic candidates; |
● |
make
milestone or other payments under our agreements, pursuant to which we have or will license or acquire rights to intellectual property
and technology; |
● |
seek
to maintain, protect, and expand our intellectual property portfolio; |
● |
seek
to attract and retain skilled personnel; |
● |
incur
the administrative costs associated with being a public company and related costs of compliance including director and officers liability
insurance required to attract and retain Board members; |
● |
create
additional infrastructure to support our operations as a commercial stage public company and our planned future commercialization
efforts; |
● |
experience
any delays or encounter issues with any of the above; and |
● |
risks
associated with delays, increased costs and funding shortages caused by or resulting from the COVID-19 pandemic; |
● |
experience
continued global disruptions associated with the conflict between Russia and Ukraine. |
We
expect to continue to incur significant expenses and losses for at least the next several years. Accordingly, we anticipate that we will
need to raise additional capital in order to obtain regulatory approval for, and the commercialization of, our therapeutic candidates.
Until such time that we can generate meaningful revenue from product sales, if ever, we expect to finance our operating activities through
public or private equity or debt financings, government or other third-party funding and other collaborations, strategic alliances and
licensing arrangements or a combination of these approaches. If we are unable to obtain funding on a timely basis, we may be required
to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any approved
therapies or products or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which
could adversely affect our business, financial condition and results of operations.
SIBV
License Agreement
In
July 2019, we entered into an option agreement with Serum International B.V. (“SIBV”), an affiliate of Serum Institute of
India Private Limited, which granted SIBV the option to license multiple programs from us and access our MabIgX® platform technology
for asset identification and selection. We received an upfront cash payment of $5 million upon execution of this option agreement. In
connection with the option agreement, SIBV made an equity investment whereby we issued 801,820 shares of our restricted common stock
in a private placement to SIBV for total gross proceeds of $10 million.
SAMR
License Agreement
In
September 2019, we entered into a License, Development and Commercialization Agreement (the “License Agreement”) with Serum
AMR Products (“SAMR”). Pursuant to the License Agreement, we received upfront payments totaling $15 million, of which $5
million was received in July 2019 through the option agreement referred to above, and we may receive milestone payments and royalty-based
payments from SAMR if certain milestones and sales levels as defined in the License Agreement are met.
Given
the equity investment by SIBV was negotiated in conjunction with the option agreement, which resulted in the execution of the License
Agreement, all arrangements were evaluated as a single agreement and amounts were allocated to the elements of the arrangement based
on their fair value. We allocated the proceeds received from the sale of the restricted common stock and upfront payment from the License
Agreement, net of issuance and contract costs, of approximately $22.5 million accordingly:
● |
we
recorded approximately $5.0 million, which represented the fair value of the restricted common stock issued of $5.4 million, net
of $441,000 of issuance costs, to stockholders’ equity within our consolidated balance sheet; |
● |
we
recorded approximately $19.6 million to deferred revenue based on the $15 million from upfront payments under the License Agreement
and approximately $4.6 million from the equity allocation; and |
● |
we
capitalized approximately $2.1 million to contract costs, which consists of approximately $376,000 issuance costs from the equity
allocation and approximately $1.7 million in other direct costs to obtain the License Agreement. |
On
May 8th, 2023, we exercised the right of termination under Section 13.3(a) for nonfulfillment of development obligations under
the contract, applicable to all products, therefore terminating the Agreement with SAMR.
CFF
License Agreement
Under
the Development Program Letter Agreement with CFF (the “CFF Agreement”), entered into in December 2016 and amended in November
2018 and December 2022 to support funding for the development of our Inhaled Gallium Citrate Anti-Infective program, we recognized revenue
of approximately $1.4 million for the year ended December 31, 2022 and $0.5 million for the year ended December 31, 2021. We expect that
any revenue we generate for the foreseeable future will fluctuate from period to period as a result of the timing of when performance
obligations and variable consideration criteria under the contract are satisfied.
Kermode
License Agreement
Under
a product discovery agreement with Kermode Biotechnologies, Inc. (“Kermode”), entered into in February 2021 to fund the discovery
of product candidates for African Swine Fever Virus (“ASFV”) with an option to include the discovery of product candidates
for swine influenza virus (“SIV”). For the years ended December 31, 2022 and 2021, the Company recognized approximately $485,000
and $465,000, respectively, in revenue related to the Kermode Agreement. The Company has recorded the remaining portion of the nonrefundable
upfront payment as a contract liability of approximately $285,000 to deferred revenue, current, as of December 31, 2022.
Gates
Foundation License Agreement
On
October 15, 2021, the Company entered into a Grant Agreement with the Bill and Melinda Gates Foundation (“Gates Foundation”).
The goal of the Grant is to develop durable approaches to block the infection and transmission of pathogens. For the years ended December
31, 2022 and 2021, respectively, the Company recognized revenue of approximately $1.2 million and 546,000 from the Grant. The Company
recorded a contract liability for the remaining consideration of approximately $183,000 to deferred revenue, current, on its consolidated
balance sheet as of December 31, 2022.
Innovative
Medicines Initiative Joint Undertaking Agreement
In
March 2021, the Company entered into an agreement (the IMI JU Agreement) with the Innovative Medicines Initiative (IMI) funded consortium
COMBACTE-NET to collaborate with other participants in a joint undertaking (the IMI JU) to combat bacterial resistance in Europe. The
project facilitates a pan-European clinical trial network to test antibiotics and other drugs to prevent and treat various infections.
This project commenced on January 1, 2013 with an initial duration of seven years. It has since been extended to October 31, 2023. The
project has 46 participants including European Federation of Pharmaceutical Industries and Associations (EFPIA) companies, universities,
research organizations, public bodies, non-profit groups, subject matter experts, and third parties.
The
academic COMBACTE-NET consortium partners initially pay for all costs incurred at EU clinical sites and subsequently bills the Company
for 25% of such costs. Specifically, we are billed for 25% of eligible costs during the entire fiscal year six to seven months following
the fiscal year. The work at these sites is performed entirely by third-party subcontractors. As such, we reimburse the 25% at the passed-through
invoice amounts. There is no reimbursement for costs incurred at non-EU sites. After October 31, 2023, the Company is committed to continuing
the trials whether or not a renewal is executed with the IMI JU. If no renewal is executed, the trials will continue without any form
of reimbursement.
For
research and development costs incurred at non-EU sites, we recognize these expenses as incurred. We recognized research and development
expense of $5.0 million and $17.5 million at non-EU sites for the year ended 2022 and 2021, respectively.
For
research and development costs incurred at EU sites, we recognize a liability for the 25% of these costs we are obligated to repay. This
amount reflects gross expenditures incurred net of contributed services to be received from the IMI JU. Research and development expense
of approximately $3.9 million and $0.2 million were incurred at EU sites for year ended December 31, 2022, and 2021 respectively. Of
this gross expense amount, the EU has contributed services of 75%, or $2.9 and $0.1 million for the year ended December 31, 2022 and
2021, respectively. Thus, our liability presented on the accompanying consolidated balance sheet is $1.0 million and $0 as of December
31, 2022 and 2021, respectively, and are presented within Other Liabilities on the accompanying consolidated balance sheets.
In-kind
contributions we make to the program will be expensed as R&D at their fair value when made. If the fair value of an in-kind contribution
we make to the IMI JU differs from its carrying amount, we will recognize a gain or loss on disposition. No gain or loss on disposition
was recognized for the year ended December 31, 2022.
The
clinical trial to which our agreement with the IMI JU has been applied to, has been put on hold.
Critical
Accounting Policies and Estimates
Our
management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or GAAP.
The
preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as
the reported expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. Such estimates include
those related to the evaluation of our ability to continue as a going concern, our best estimate of standalone selling price of revenue
deliverables, useful life of long lived assets, classification of deferred revenue, income taxes, assumptions used in the Black Scholes
Merton option pricing model to calculate the fair value of stock based compensation, deferred tax asset valuation allowances, and preclinical
study and clinical trial accruals. We base our estimates on historical experience and on various other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.
We
define our critical accounting policies as those accounting principles generally accepted in the United States that require us to make
subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition
and results of operations as well as the specific manner in which we apply those principles. Our critical accounting policies are primarily
for revenue recognition and accrued research and development costs. We believe the significant accounting policies used in the preparation
of our consolidated financial statements are as follows:
Revenue
Recognition
We
recognize revenue based on Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC
606”), which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as
leases, insurance, collaboration arrangements and financial instruments.
To
determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue at a point in time,
or over time, as the entity satisfies performance obligations. We only apply the five-step model to contracts when it is probable that
we will collect the consideration it is entitled to in exchange for the goods or services we transfer to the customer. At contract inception,
once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract, determine
those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the
amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is
satisfied.
As
part of the accounting for customer arrangements, we must use judgment to determine: a) the number of performance obligations based on
the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the standalone selling price for each
performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. We use judgment to
determine whether milestones or other variable consideration should be included in the transaction price.
The
transaction price is allocated to each performance obligation on a relative standalone selling price basis. In developing the standalone
price for a performance obligation, we consider applicable market conditions and relevant entity-specific factors, including factors
that were contemplated in negotiating the agreement with the customer and estimated costs. We recognize revenue as or when the performance
obligations under the contract are satisfied. We receive payments from our customers based on payment schedules established in each contract.
We record any amounts received prior to satisfying the revenue recognition criteria as deferred revenue on the consolidated balance sheet.
Amounts recognized as revenue, but not yet received or invoiced are recorded within other receivables on the consolidated balance sheet.
Amounts are recorded as other receivables on the consolidated balance sheet when our right to consideration is unconditional. We do not
assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between
payment by the customer and the transfer of a majority of the promised goods or services to the customer will be one year or less.
Research
and Development Expenses
We
recognize research and development expenses to operations as they are incurred. Our research and development expenses consist primarily
of:
● |
salaries
and related overhead expenses, which include stock-based compensation and benefits for personnel in research and development functions; |
● |
fees
paid to consultants and contract research organizations, or CROs, including in connection with our preclinical studies and clinical
trials and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial
material management and statistical compilation and analyses; |
● |
costs
related to acquiring and manufacturing clinical trial materials; |
● |
costs
related to compliance with regulatory requirements; and |
● |
payments
related to licensed products and technologies. |
Costs
for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information
and data provided to us by our vendors and clinical sites. Nonrefundable advance payments for goods or services to be received in future
periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the
related goods are delivered or when the services are performed.
We
plan to increase our research and development expenses for the foreseeable future as we continue to develop our therapeutic programs,
and subject to the availability of additional funding, further advance the development of our therapeutic candidates for additional indications
and begin to conduct clinical trials.
The
process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful
development of our therapeutic candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs
of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any
of our therapeutic candidates.
Stock-Based
Compensation
We
recognize compensation expense for all stock-based awards based on the grant-date estimated fair values, which we determine using the
Black Scholes Merton option pricing model, on a straight-line basis over the requisite service period for the award. We account for forfeitures
as they occur.
The
Black Scholes Merton option pricing model incorporates various highly sensitive assumptions, including the fair value of our common stock,
expected volatility, expected term and risk-free interest rates. The weighted average expected life of options was calculated using the
simplified method as prescribed by the SEC’s Staff Accounting Bulletin, Topic 14 (“SAB Topic 14”). This decision was
based on the lack of relevant historical data due to our limited historical experience. In addition, due to our limited historical data,
the estimated volatility also reflects the application of SAB Topic 14, incorporating the historical volatility of comparable companies
whose stock prices are publicly available. The risk-free interest rate for the periods within the expected term of the option is based
on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as we have never declared or paid dividends and
have no plans to do so in the foreseeable future.
Income
Taxes
We
account for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the
difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in
which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax
assets to the amounts expected to be realized. For the years ended December 31, 2022 and 2021, no income tax expense or benefit was recognized,
primarily due to a full valuation allowance recorded against the net deferred tax asset.
We
assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are
still subject to assessment or challenge by the relevant taxing authorities. Assessing an uncertain tax position begins with the initial
determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent
likely of being realized upon ultimate settlement. At each balance sheet date, unresolved uncertain tax positions must be reassessed,
and we determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized benefit
is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition
and measurement of a tax benefit might change as new information becomes available.
Going
Concern
We
assess and determine our ability to continue as a going concern under the provisions of ASC 205-40, Presentation of Financial Statements-Going
Concern, which requires us to evaluate whether there are conditions or events that raise substantial doubt about our ability to continue
as a going concern within one year after the date that our annual and interim consolidated financial statements are issued. Certain additional
financial statement disclosures are required if such conditions or events are identified. If and when an entity’s liquidation becomes
imminent, financial statements should be prepared under the liquidation basis of accounting.
Determining
the extent, if any, to which conditions or events raise substantial doubt about our ability to continue as a going concern, or the extent
to which mitigating plans sufficiently alleviate any such substantial doubt, as well as whether or not liquidation is imminent, requires
significant judgment by us.
We
do not have sufficient cash on hand and available liquidity to meet our obligations through the twelve months following the date the
consolidated financial statements are issued. Therefore, this condition raises substantial doubt about our ability to continue as a going
concern. Management’s plans were updated to evaluate different strategies to obtain the required funding of future operations.
These plans may include, but are not limited to, additional funding from current or new investors; however, if we are unable to raise
additional funding to meet working capital needs, we will be forced to delay or reduce the scope of our research programs and/or limit
or cease operations. The negative cash flows and lack of financial resources raised substantial doubt as to our ability to continue as
a going concern, and that substantial doubt has not been alleviated. Therefore, this condition raises substantial doubt about our ability
to continue as a going concern. See Note 1 to the Company’s Consolidated Financial Statements, “Going Concern” for
further details.
Our
estimated cash and cash equivalents were approximately $1.5 million as of April 30, 2023. We are currently in discussions with financing
sources in an attempt to secure short-term financing to continue operations and fund other liquidity needs. In the absence of such financing,
management anticipates that existing cash resources will not be sufficient to meet operating and liquidity needs on or before June 30,
2023. However, management is currently evaluating various cost reduction actions, including additional reductions in the Company’s
workforce and suspending research and development expenditures on one or more product candidates, in order to reduce our expenditures
and preserve cash. We are not able to predict whether any such cost reduction actions will be successful.
As
a result of our current liquidity position, management can provide no assurance that we will be able to obtain financing on acceptable
terms, if at all. If financing is available, it may not be on favorable terms and may have a significant dilutive effect on our existing
stockholders. In the event we are unable to secure financing sufficient to allow us to meet our obligations as they become due, we may
need to file a voluntary petition for relief under the United States Bankruptcy Code in order to implement a restructuring plan or liquidation.
Management’s
Discussion and Analysis of Financial Condition and Results of Operations - March 31, 2022
(In
thousands, except share and per share amounts)
Restated
| |
Three Months Ended March
31, 2022 | |
| |
As Previously Reported | | |
Adjusted Balance | | |
As Restated | |
Revenue: | |
| | | |
| | | |
| | |
Grant Revenue | |
$ | 1,187 | | |
$ | - | | |
$ | 1,187 | |
Operating expenses: | |
| | | |
| | | |
| | |
Research and Development | |
| 6,450 | | |
| - | | |
| 6,450 | |
General and administrative | |
| 2,161 | | |
| - | | |
| 2,161 | |
Total operating expenses | |
| 8,611 | | |
| - | | |
| 8,611 | |
Loss from operations | |
| (7,424 | ) | |
| - | | |
| (7,424 | ) |
Other income (expense): | |
| | | |
| | | |
| | |
Interest (expense), net | |
| (248 | ) | |
| (134 | ) | |
| (382 | ) |
Other income, net | |
| 22 | | |
| - | | |
| 22 | |
Gain on valuation of notes payable | |
| - | | |
| 250 | | |
| 250 | |
Change in fair value of notes payable | |
| (116 | ) | |
| 68 | | |
| (48 | ) |
Net loss | |
$ | (7,766 | ) | |
$ | 184 | | |
$ | (7,582 | ) |
Weighted-average common shares outstanding used in computing net loss per share available to common
stockholders, basic and diluted | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | |
Net loss per share to common stockholders, basic and diluted | |
$ | (0.44 | ) | |
| 0.01 | | |
| (0.43 | ) |
| |
| | | |
| | | |
| | |
Net loss | |
$ | (7,766 | ) | |
$ | 184 | | |
$ | (7,582 | ) |
Other comprehensive income | |
| - | | |
| 84 | | |
| 84 | |
Total comprehensive (loss) income | |
| (7,766 | ) | |
| 268 | | |
| (7,498 | ) |
Comparison
of the Three Months Ended March 31, 2022 and 2021
The
following table summarizes our results of operations for the three months ended March 31, 2022 and 2021 (in thousands):
| |
Three Months Ended | | |
| |
| |
March 31, | | |
| |
| |
2022 (as
restated) | | |
2021 | | |
Change $ | |
| |
(unaudited) | | |
(unaudited) | | |
| |
Revenue: | |
| | | |
| | | |
| | |
Grant revenue | |
$ | 1,187 | | |
$ | - | | |
$ | 1,187 | |
Operating expenses: | |
| | | |
| | | |
| | |
Research and development | |
| 6,450 | | |
| 4,955 | | |
| 1,495 | |
General and administrative | |
| 2,161 | | |
| 1,944 | | |
| 217 | |
Total operating expenses | |
| 8,611 | | |
| 6,899 | | |
| 1,712 | |
Loss from operations | |
| (7,424 | ) | |
| (6,899 | ) | |
| (525 | ) |
Other income (expense): | |
| | | |
| | | |
| | |
Interest income, net | |
| (382 | ) | |
| 1 | | |
| (383 | ) |
Other income | |
| 22 | | |
| 7 | | |
| 15 | |
Gain on valuation of notes payable | |
| 250 | | |
| - | | |
| 250 | |
Change in fair value of notes payable | |
| (48 | ) | |
| - | | |
| (48 | ) |
Net loss | |
$ | (7,582 | ) | |
$ | (6,891 | ) | |
$ | (691 | ) |
Deemed dividends | |
| - | | |
| (986 | ) | |
| 986 | |
Net loss available to common stockholders | |
$ | (7,582 | ) | |
$ | (7,877 | ) | |
$ | 295 | |
Weighted-average common shares outstanding used in computing net loss per share available to common
stockholders, basic and diluted | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | |
Net (loss) income per share to common stockholders, basic and diluted | |
| (0.43 | ) | |
| (0.44 | ) | |
| .01 | |
| |
| | | |
| | | |
| | |
Net loss available to common stockholders | |
$ | (7,582 | ) | |
$ | (7,877 | ) | |
$ | 295 | |
Other comprehensive income | |
| 84 | | |
| - | | |
| 84 | |
Total comprehensive (loss) income | |
$ | (7,498 | ) | |
$ | (7,877 | ) | |
$ | 379 | |
Grant
Revenue. Grant revenue was $1.2 million and $0 for the three-month period ended March 31, 2022 and the three-month period ended March
31, 2021. The three months ended March 31, 2022 included revenue from CFF, Kermode and Gates.
Research
and Development Expenses. Research and development expenses increased by approximately $1.5 million from approximately $5.0 million
for the three months ended March 31, 2021 to approximately $6.5 million for the three months ended March 31, 2022 due primarily to:
|
● |
an
increase of approximately $1.0 million for drug manufacturing expenses for our Phase 3 |
|
|
|
|
● |
clinical
trial evaluating AR-320 for the prevention of VAP; an increase of approximately $0.8 million in other spending in preparation for |
|
|
|
|
● |
the
initiation of the AR-320 Phase 3 clinical trial; and an increase of approximately $0.5 million in manufacturing of clinical supplies
for the initiation of a Phase 1 clinical trial evaluating AR-701 for the treatment of COVID-19. |
These
increases were partially offset by:
|
● |
a
decrease of approximately $0.7 million in spending on clinical trial activities and drug manufacturing expenses for the Phase 3 study
of our AR-301 program; and |
|
|
|
|
● |
a
decrease of approximately $0.1 million in spending on our ongoing Phase 2a clinical trial evaluating AR-501 for the treatment of
cystic fibrosis. |
General
and Administrative Expenses. General and administrative expenses increased by approximately $217,000 from approximately $1.9 million
for the three months ended March 31, 2021 to approximately $2.2 million for the three months ended March 31, 2022 which was due primarily
to increases in personnel related costs and professional service fees.
Interest
Expense, Net. Interest expense, net increased by approximately $383,000 from $1,000 income for the three months ended March 31, 2021
to $382,000 expense for the three months ended March 31, 2022. The expense increase for the quarter ended March 31, 2022 as compared
to the quarter ended March 31, 2021 is primarily due to the original issue discount on the Note Purchase Agreement with Streeterville
Capital, LLC .
Change
in Fair Value of Note Payable. This relates primarily to the change in fair value of the note payable pursuant to the Note Purchase
Agreement with Streeterville Capital, LLC for the three months ended March 31, 2022.
Other
Income. Other income increased by approximately $15,000 from $7,000 for the three months ended March 31, 2021 to approximately $22,000
for the three months ended March 31, 2022. The increase was primarily related to sublease income from a sublease agreement we entered
into with a tenant on March 1, 2021 to sublet a small portion of our Los Gatos facility.
Other
Comprehensive Income. Other comprehensive income increased from $0 for the three months ended March 31, 2021 to $84,000 for the three
months ended March 31, 2022. This relates to the change in credit risk calculated by our fair value option valuation for the Note Purchase
Agreements with Streeterville Capital, LLC.
Management’s
Discussion and Analysis of Financial Condition and Results of Operations - June 30, 2022
(In
thousands, except share and per share amounts)
Restated
| |
Three Months Ended June 30,
2022 | | |
Six Months Ended June 30,
2022 | |
| |
As Previously Reported | | |
Adjusted Balance | | |
As Restated | | |
As Previously Reported | | |
Adjusted Balance | | |
As Restated | |
Revenue: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Grant Revenue | |
$ | 292 | | |
$ | - | | |
$ | 292 | | |
$ | 1,479 | | |
$ | - | | |
$ | 1,479 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Research and Development | |
| 6,348 | | |
| - | | |
| 6,348 | | |
| 12,798 | | |
| - | | |
| 12,798 | |
General and administrative | |
| 1,681 | | |
| - | | |
| 1,681 | | |
| 3,842 | | |
| - | | |
| 3,842 | |
Total operating expenses | |
| 8,029 | | |
| - | | |
| 8,029 | | |
| 16,640 | | |
| - | | |
| 16,640 | |
Loss from operations | |
| (7,737 | ) | |
| - | | |
| (7,737 | ) | |
| (15,161 | ) | |
| - | | |
| (15,161 | ) |
Other income (expense): | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Interest income (expense), net | |
| 8 | | |
| 273 | | |
| 281 | | |
| (240 | ) | |
| 139 | | |
| (101 | ) |
Other income, net | |
| 23 | | |
| - | | |
| 23 | | |
| 45 | | |
| - | | |
| 45 | |
Gain on valuation of notes payable | |
| - | | |
| - | | |
| - | | |
| - | | |
| 250 | | |
| 250 | |
Change in fair value of notes payable | |
| (273 | ) | |
| 588 | | |
| 315 | | |
| (389 | ) | |
| 656 | | |
| 267 | |
Net (loss) income | |
$ | (7,979 | ) | |
$ | 861 | | |
$ | (7,118 | ) | |
$ | (15,745 | ) | |
$ | 1,045 | | |
$ | (14,700 | ) |
Weighted-average common shares outstanding used in computing net loss per share available to common
stockholders, basic and diluted | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | |
Net loss per share to common stockholders, basic and diluted | |
$ | (0.45 | ) | |
$ | 0.05 | | |
$ | (0.40 | ) | |
$ | (0.89 | ) | |
$ | 0.06 | | |
$ | (0.83 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net (loss) income | |
$ | (7,979 | ) | |
$ | 861 | | |
$ | (7,118 | ) | |
$ | (15,745 | ) | |
$ | 1,045 | | |
$ | (14,700 | ) |
Other comprehensive income | |
| - | | |
| 1,760 | | |
| 1,760 | | |
| - | | |
| 1,844 | | |
| 1,844 | |
Total comprehensive (loss) income | |
$ | (7,979 | ) | |
$ | 2,621 | | |
$ | (5,358 | ) | |
$ | (15,745 | ) | |
$ | 2,889 | | |
$ | (12,856 | ) |
Comparison
of the Three Months Ended June 30, 2022 and 2021
The
following table summarizes our results of operations for the three months ended June 30, 2022 and 2021 (in thousands):
| |
Three Months Ended | | |
| |
| |
June 30, | | |
| |
| |
2022 (as restated) | | |
2021 | | |
Change $ | |
| |
(unaudited) | | |
(unaudited) | | |
| |
Revenue: | |
| | | |
| | | |
| | |
Grant revenue | |
$ | 292 | | |
$ | - | | |
$ | 292 | |
License revenue | |
| - | | |
| 33 | | |
| (33 | ) |
Total revenue | |
| 292 | | |
| 33 | | |
| 259 | |
Operating expenses: | |
| | | |
| | | |
| | |
Research and development | |
| 6,348 | | |
| 4,573 | | |
| 1,775 | |
General and administrative | |
| 1,681 | | |
| 1,694 | | |
| (13 | ) |
Total operating expenses | |
| 8,029 | | |
| 6,267 | | |
| 1,762 | |
Loss from operations | |
| (7,737 | ) | |
| (6,234 | ) | |
| (1,503 | ) |
Other income (expense): | |
| | | |
| | | |
| | |
Interest income, net | |
| 281 | | |
| - | | |
| 281 | |
Other income | |
| 23 | | |
| 22 | | |
| 1 | |
Gain on extinguishment of Paycheck Protection Program loan | |
| - | | |
| 722 | | |
| (722 | ) |
Change in fair value of notes payable | |
| 315 | | |
| - | | |
| 315 | |
Net loss | |
$ | (7,118 | ) | |
$ | (5,490 | ) | |
$ | (1,628 | ) |
Weighted-average common shares outstanding used in computing net loss per share available to common
stockholders, basic and diluted | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | |
Net loss per share to common stockholders, basic and diluted | |
| (0.40 | ) | |
| (0.31 | ) | |
| (0.09 | ) |
| |
| | | |
| | | |
| | |
Net loss | |
$ | (7,118 | ) | |
$ | (5,490 | ) | |
$ | (1,628 | ) |
Other comprehensive income | |
| 1,760 | | |
| - | | |
| 1,760 | |
Total comprehensive (loss) income | |
$ | (5,358 | ) | |
$ | (5,490 | ) | |
$ | 132 | |
Grant
Revenue. Grant revenue increased to $0.3 million for the three months ended June 30, 2022 from zero for the three months ended June
30, 2021 primarily due to the recognition of revenue from grants from the Cystic Fibrosis Foundation (CFF), the Gates Foundation, as
well as from Kermode Biotechnologies, Inc., an ʎPEX technology licensee, during the second quarter of 2022. There was no recognition
of grant revenue during the second quarter of 2021.
License
Revenue. There was no recognition of license revenue during the second quarter of 2022 and $33,000 was recognized for license revenue
for the three months ended June 30, 2021. The recognition of revenue was related to the out-licensing and product discovery agreement,
and a statement of work, with Kermode Biotechnologies, Inc. (“Kermode”) (collectively, the “Kermode Agreement”),
which was entered into in February 2021.
Research
and Development Expenses. Research and development expenses increased by approximately $1.8 million from approximately $4.6 million
for the three months ended June 30, 2021 to approximately $6.3 million for the three months ended June 30, 2022 due primarily to:
|
● |
an
increase of approximately $1.3 million in spending on our ongoing Phase 2a clinical trial evaluating AR-501 for the treatment of
cystic fibrosis; |
|
● |
an
increase of approximately $0.4 million in spending on clinical trial activities evaluating AR-320 for the prevention of VAP; |
|
● |
an
increase of approximately $0.3 million in spending on clinical trial activities and drug manufacturing expenses for Phase 3 study
of our AR-301 program; and |
|
● |
an
increase of approximately $0.1 million in salaries and related overhead expenses, which include stock-based compensation and benefits
for personnel in research and development functions. |
These
increases were partially offset by:
|
● |
a
decrease of approximately $0.3 million in license and permit fees; and |
|
● |
a
decrease of approximately $0.3 million for evaluating AR-701 for the treatment of COVID-19. |
General
and Administrative Expenses. General and administrative expenses decreased by approximately $13,000 from approximately $1.69 million
for the three months ended June 30, 2021 to approximately $1.68 million for the three months ended June 30, 2022 which were due primarily
to decreases in stock compensation expense and Delaware franchise taxes offset by increases in personnel related costs and in liability
insurance.
Interest
Income (Expense),Net. Net interest income was approximately $8,000 for the quarter ended June 30, 2022 compared to zero interest
income for the quarter ended June 30, 2021. The interest income was primarily due to interest earned on our cash-on-hand during the second
quarter of 2022.
Other
Income. Other income increased to $23,000 for the quarter ended June 30, 2022 from approximately $22,000 for the quarter ended June
30, 2021. The income was primarily due to a sublease agreement we entered into with a tenant in March 2021 to sublet a small portion
of our Los Gatos facility.
Gain
on Extinguishment of Paycheck Protection Program Loan. There was no extinguishment of debt for the quarter ended June 30, 2022. Gain
on extinguishment of the Paycheck Protection Program loan was approximately $722,000 for the quarter ended June 30, 2021.
Change
in Fair Value of Note Payable: Change in fair value of note payable increased by $273,000 for the quarter ended June 30, 2022 compared
to zero for the quarter ended June 30, 2021. The increase was due to an updated fair valuation calculation for outstanding debt.
Other
Comprehensive Income. Other comprehensive income increased from $0 for the three months ended June 30, 2021 to $1,760,000 for the
three months ended June 30, 2022. This relates to the change in credit risk calculated by our fair value option valuation for the Note
Purchase Agreements with Streeterville Capital, LLC.
Comparison
of the Six Months Ended June 30, 2022 and 2021
The
following table summarizes our results of operations for the six months ended June 30, 2022 and 2021 (in thousands):
| |
Six Months Ended | | |
| |
| |
June 30, | | |
| |
| |
2022 (as restated) | | |
2021 | | |
Change $ | |
| |
(unaudited) | | |
(unaudited) | | |
| |
Revenue: | |
| | | |
| | | |
| | |
Grant revenue | |
$ | 1,479 | | |
$ | - | | |
$ | 1,479 | |
License revenue | |
| - | | |
| 33 | | |
| (33 | ) |
Total revenue | |
| 1,479 | | |
| 33 | | |
| 1,446 | |
Operating expenses: | |
| | | |
| | | |
| | |
Research and development | |
| 12,798 | | |
| 9,528 | | |
| 3,270 | |
General and administrative | |
| 3,842 | | |
| 3,638 | | |
| 204 | |
Total operating expenses | |
| 16,640 | | |
| 13,166 | | |
| 3,474 | |
Loss from operations | |
| (15,161 | ) | |
| (13,133 | ) | |
| (2,028 | ) |
Other income (expense): | |
| | | |
| | | |
| | |
Interest expense, net | |
| (101 | ) | |
| 1 | | |
| (102 | ) |
Other income | |
| 45 | | |
| 29 | | |
| 16 | |
Gain on extinguishment of Paycheck Protection Program loan | |
| - | | |
| 722 | | |
| (722 | ) |
Gain/ on valuation of notes payable | |
| 250 | | |
| - | | |
| 250 | |
Change in fair value of notes payable | |
| 267 | | |
| - | | |
| 267 | |
Net loss | |
$ | (14,700 | ) | |
$ | (12,381 | ) | |
$ | (2,319 | ) |
Deemed dividends | |
| - | | |
| (986 | ) | |
| 986 | |
Net loss available to common stockholders | |
$ | (14,700 | ) | |
$ | (13,367 | ) | |
$ | (1,333 | ) |
Weighted-average common shares outstanding used in computing net loss per share available to common
stockholders, basic and diluted | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | |
Net loss per share to common stockholders, basic and diluted | |
| (0.83 | ) | |
| (0.76 | ) | |
| (0.07 | ) |
| |
| | | |
| | | |
| | |
Net loss available to common stockholders | |
$ | (14,700 | ) | |
$ | (13,367 | ) | |
$ | (1,333 | ) |
Other comprehensive income | |
| 1,844 | | |
| - | | |
| 1,844 | |
Total comprehensive loss | |
$ | (12,856 | ) | |
$ | (13,367 | ) | |
$ | 511 | |
Grant
Revenue. Grant revenue increased to $1.5 million for the six months ended June 30, 2022 from zero for the six months ended June 30,
2021 primarily due to the recognition of revenue from grants from the Cystic Fibrosis Foundation (CFF) and the Gates Foundation, as well
as from Kermode Biotechnologies, Inc., an ʎPEX technology licensee and no recognition of grant revenue during the first half of
2021.
License
Revenue. License revenue was zero for the six months ended June 30, 2022 compared to $33,000 for the six months ended June 30, 2021
primarily due to the recognition of revenue related to the Kermode Agreement, which was entered into in February 2021.
Research
and Development Expenses. Research and development expenses increased by approximately $3.3 million from approximately $9.5 million
for the six months ended June 30, 2021 to approximately $12.8 for the six months ended June 30, 2022 due primarily to:
|
● |
an
increase of approximately $2.2 million in spending on clinical trial activities evaluating AR-320 for the prevention of VAP; |
|
● |
an
increase of approximately $1.2 million in spending on clinical trial activities and drug manufacturing expenses for the Phase 2a
study of our AR-501 program; |
|
● |
an
increase of approximately $0.4 million in spending on research and development activities for our COVID-19 programs; |
|
● |
an
increase of approximately $0.4 million in personnel, consulting and other related costs; and |
|
● |
an
increase of approximately $0.1 million in spending on research and development lab fees. |
These
increases were partially offset by:
|
● |
a
decrease of approximately $0.6 million in license and permit fees; and |
|
● |
a
decrease of approximately $0.4 million in spending on clinical trial activities and drug manufacturing expenses for the Phase 3 study
of our AR-301 program. |
General
and Administrative Expenses. General and administrative expenses increased by approximately $204,000 from approximately $3.6 million
for the six months ended June 30, 2021 to approximately $3.8 million for the six months ended June 30, 2022 which was due primarily to
increases in personnel related costs, liability insurance, professional service fees, offset by Delaware franchise taxes.
Interest
Income (Expense), Net. Interest expense, net increased by approximately $102,000 from $1,000 for the six months ended June 30, 2021
to approximately $101,000 for the six months ended June 30, 2022. The increase was primarily due to debt servicing during the second
quarter of 2022.
Other
Income. Other income increased by approximately $16,000 from $29,000 for the six months ended June 30, 2021 to approximately $45,000
for the six months ended June 30, 2022. The increase was primarily related to income from a sublease agreement we entered into with a
tenant on March 1, 2021 to sublet a small portion of our Los Gatos facility.
Gain
on Extinguishment of Paycheck Protection Program Loan. There was no extinguishment of debt in 2022. Gain on extinguishment of the
PPP loan of approximately $722,000 for the six months ended June 30, 2021 is related to the forgiveness of our loan from the Small Business
Administration and release of financial obligation from our lender, Silicon Valley Bank, in May 2021.
Change
in Fair Value of Note Payable: Change in fair value of note payable increased by $267,000 for the six months ended June 30, 2022
compared to zero for the six months ended June 30, 2021. The increase was due to an updated fair valuation calculation for our outstanding
debt.
Other
Comprehensive Income. Other comprehensive income increased from $0 for the six months ended June 30, 2021 to $1,844,000 for the six
months ended June 30, 2022. This relates to the change in credit risk calculated by our fair value option valuation for the Note Purchase
Agreements with Streeterville Capital, LLC.
Management’s
Discussion and Analysis of Financial Condition and Results of Operations - September 30, 2022
(In
thousands, except share and per share amounts)
Restated
| |
Three Months Ended September
30, 2022 | | |
Nine Months Ended September
30, 2022 | |
| |
As Previously Reported | | |
Adjusted Balance | | |
As Restated | | |
As Previously Reported | | |
Adjusted Balance | | |
As Restated | |
Revenue: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Grant Revenue | |
$ | 399 | | |
$ | - | | |
$ | 399 | | |
$ | 1,878 | | |
$ | - | | |
$ | 1,878 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Research and Development | |
| 6,118 | | |
| - | | |
| 6,118 | | |
| 18,916 | | |
| - | | |
| 18,916 | |
General and administrative | |
| 1,693 | | |
| - | | |
| 1,693 | | |
| 5,535 | | |
| - | | |
| 5,535 | |
Total operating expenses | |
| 7,811 | | |
| - | | |
| 7,811 | | |
| 24,451 | | |
| - | | |
| 24,451 | |
Loss from operations | |
| (7,412 | ) | |
| - | | |
| (7,412 | ) | |
| (22,573 | ) | |
| - | | |
| (22,573 | ) |
Other income (expense): | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Interest income (expense), net | |
| (27 | ) | |
| 868 | | |
| 841 | | |
| (267 | ) | |
| 1,007 | | |
| 740 | |
Other income, net | |
| 23 | | |
| - | | |
| 23 | | |
| 68 | | |
| - | | |
| 68 | |
Gain on valuation of notes payable | |
| - | | |
| - | | |
| - | | |
| - | | |
| 250 | | |
| 250 | |
Change in fair value of notes payable | |
| (823 | ) | |
| 2,195 | | |
| 1,372 | | |
| (1,212 | ) | |
| 2,851 | | |
| 1,639 | |
Net (loss) income | |
$ | (8,239 | ) | |
$ | 3,063 | | |
$ | (5,176 | ) | |
$ | (23,984 | ) | |
$ | 4,108 | | |
$ | (19,876 | ) |
Weighted-average common shares outstanding used in computing net loss per
share available to common stockholders, basic and diluted | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | |
Net loss per share to common stockholders, basic and diluted | |
$ | (0.47 | ) | |
$ | 0.17 | | |
$ | (0.30 | ) | |
$ | (1.35 | ) | |
$ | 0.23 | | |
$ | (1.12 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net (loss) income | |
$ | (8,239 | ) | |
$ | 3,063 | | |
$ | (5,176 | ) | |
$ | (23,984 | ) | |
$ | 4,108 | | |
$ | (19,876 | ) |
Other comprehensive (loss) income | |
| - | | |
| (104 | ) | |
| (104 | ) | |
| - | | |
| 1,740 | | |
| 1,740 | |
Total comprehensive (loss) income | |
$ | (8,239 | ) | |
$ | 2,959 | | |
$ | (5,280 | ) | |
$ | (23,984 | ) | |
$ | 5,848 | | |
$ | (18,136 | ) |
Comparison
of the Three Months Ended September 30, 2022 and 2021
The
following table summarizes our results of operations for the three months ended September 30, 2022 and 2021 (in thousands):
| |
Three Months Ended | | |
| |
| |
September 30, | | |
| |
| |
2022 (as restated) | | |
2021 | | |
Change $ | |
| |
(unaudited) | | |
(unaudited) | | |
| |
Revenue: | |
| | | |
| | | |
| | |
Grant revenue | |
$ | 399 | | |
$ | 515 | | |
$ | (116 | ) |
Operating expenses: | |
| | | |
| | | |
| | |
Research and development | |
| 6,118 | | |
| 19,842 | | |
| (13,724 | ) |
General and administrative | |
| 1,693 | | |
| 1,699 | | |
| (6 | ) |
Total operating expenses | |
| 7,811 | | |
| 21,541 | | |
| (13,730 | ) |
Loss from operations | |
| (7,412 | ) | |
| (21,026 | ) | |
| 13,614 | |
Other income (expense): | |
| | | |
| | | |
| | |
Interest income (expense), net | |
| 841 | | |
| 1 | | |
| 840 | |
Other income | |
| 23 | | |
| 23 | | |
| - | |
Change in fair value of notes payable | |
| 1,372 | | |
| - | | |
| 1,372 | |
Net (loss) income | |
$ | (5,176 | ) | |
$ | (21,002 | ) | |
$ | 15,826 | |
Deemed dividends | |
| - | | |
| (3,141 | ) | |
| 3,141 | |
Net (loss) income available to common stockholders | |
$ | (5,176 | ) | |
$ | (24,143 | ) | |
$ | 18,967 | |
Weighted-average common shares outstanding used in computing net loss per share available to common
stockholders, basic and diluted | |
| 17,701,592 | | |
| 17,701,592 | | |
| 17,701,592 | |
Net (loss) income per share to common stockholders, basic and diluted | |
| (0.29 | ) | |
| (1.36 | ) | |
| 1.07 | |
| |
| | | |
| | | |
| | |
Net (loss) income available to common stockholders | |
$ | (5,176 | ) | |
$ | (24,143 | ) | |
$ | 18,967 | |
Other comprehensive loss | |
| (104 | ) | |
| - | | |
| (104 | ) |
Total comprehensive (loss) income | |
$ | (5,280 | ) | |
$ | (24,143 | ) | |
$ | 18,863 | |
Grant
Revenue. Grant revenue remained at $0.4 million for the three months ended September 30, 2022 compared to $0.5 million for the three
months ended September 30, 2021 primarily due to the recognition of revenue from grants from the Cystic Fibrosis Foundation (CFF), the
Gates Foundation, as well as from Kermode Biotechnologies, Inc., during the third quarter of 2022.